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ABSTRACT 
Patrick Dib, M.S., Department of Biological Sciences, Wright State University, 2008. 
The effects of a nutritional supplement, Mass FX, on muscular strength, body 
composition, and blood chemistries in resistance trained adult males 
 
The purpose of this study was to determine the effects of a nutritional supplement, Mass 
FX, on muscular strength, body composition, and blood chemistries in resistance-trained 
adult males. Eight subjects, mean age 25 +/- 3.02 years, were randomly assigned to two 
groups (n=4). Each group was given either Mass FX or a Placebo in a double-blind 
manner to be taken orally for six weeks  (4caps/day regardless of bodyweight). For the 
duration of the study, both groups were following the same training program and a diet 
customized to each subject’s bodyweight in conjunction to the supplementation. Data 
were analyzed using Analysis of Covariance (ANCOVA) with a Bonferroni correction 
resulting in a family-wise level of significance of α = 0.05, to avoid inflation of the Type 
I error. To confirm results, an independent samples t-test using a Bonferroni correction 
with a family-wise level of significance of α=0.05 was performed. Using ANCOVA, the 
groups were significantly different for the Bench Press outcome; whereas using the 
independent samples t-test, the two groups were significantly different for Bench Press 
and Free Testosterone. The results of this study indicate that supplementation with Mass 
FX induced better improvements than Placebo in muscular strength as measured by the 
bench press (p<0.05). Other measures in muscular strength, body composition, and free 
testosterone showed improvements, but were not statistically significant (p>0.05). No 
adverse effects on selected clinical health markers: complete blood count with 
differential, hepatic (AST, ALP, ALT), lipids (TC, TGs, LDL, VLDL), and renal 
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(creatinine, BUN) were observed from Mass FX supplementation (Group significance 
p>0.05). Mean difference (Post-Pre) in total and free testosterone concentrations 
exhibited apparent increases in the Mass FX group, in contrast to Placebo in which 
reductions in both mean difference total and free testosterone concentrations were 
observed. Lack of significance in the remaining variables of interest could be attributed to 
low power because of the small sample size used in this study. Thus, due to limitations in 
terms of sample representation and size, this study should be considered a pilot study. 
Future studies need to investigate these parameters using larger sample sizes. 
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CHAPTER I 
INTRODUCTION 
The desire to enhance performance and physical appearance has been a mission 
sought since the ancient times. An approach used to achieve these aforementioned goals 
includes the use of dietary supplements. Paintings of Shen-Nung, a Chinese emperor, 
dating back to 2737 B.C. show him with leaves of Ma Huang. Ma Huang, commonly 
known as ephedra, is a plant that has stimulant properties. Ephedra was a very popular 
supplement used by individuals seeking weight loss and improved performance until its 
ban in 2004 (De Rose, 2008). Athletes during 500-400 B.C used to consume animal 
organs believing they would become more courageous and stronger (Applegate & 
Grivetti, 1997).  Greek wrestlers ingested sesame seeds with meat in efforts to build more 
muscle (Carpenter, 2007). Andean Indians consumed coca leaves to prevent fatigue 
(Carpenter, 2007). In addition, there has been mention in Norwegian literature that 
Viking warriors used hallucinogenic mushrooms to prepare for battle (Prokop, 1970). 
Today, the ways have changed, yet the purpose has stayed the same – physique and 
performance enhancement.  
Ancient practices lacked scientific background. However, currently with advances 
in science, medicine, and food technology, new forms of ergogenic aids started to 
emerge. During the 1940’s and 1950’s, testosterone and its analogues made their way 
through sports after the successful synthesis of testosterone in the 1930’s (Carpenter, 
2007). During this period, the Soviet athletes were dominating in world competitions. In 
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efforts to beat the Soviets in sporting events, the United States sought to research and 
develop potent anabolic steroids. One of the major steroid discoveries was the 
introduction of methandrostenalone (Dianabol) by an American physician Dr. John 
Zeigler (McDuff & Barron, 2005). Since then, anabolic steroids have become a major 
concern and problem in sports.  
In addition to anabolic steroids, stimulant use in the form of amphetamines and 
other sympathimimetic amines by athletes has been popular since the 1940’s (McDuff & 
Barron, 2005). Their use ranged from weight loss (physique enhancement and making 
weight) to improved energy levels (improved athletic performance). Another substance 
used to enhance performance especially in endurance events is erythropoietin (Elliot, 
2008). EPO, a peptide hormone, has been shown to increase red blood cell counts. This 
translates into better oxygen saturation and supply to skeletal muscle tissue and in turn 
improves performance (Elliot, 2008).  
Despite the ergogenic benefits of these compounds, they pose a major health, 
legal, and moral problem (Laure & Biosinger, 2005). It is noteworthy to mention that not 
only are elite professional athletes abusing these controlled substances, but both male and 
female teens and pre-adolescents are using them, too (Carpenter, 2007). With this in 
mind, there is a clear concern to offer solutions to this problem. Thus, there is a need for 
the scientific community to provide research on legal alternative products such as dietary 
supplements that would improve athletic performance with no adverse effects on health. 
In turn, this will help in reducing the alarming prevalence in which banned substances are 
being abused. 
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Testosterone 
Testosterone, a 19-carbon steroid, is the primary male sex hormone (Chang, 2002, 
p.1-2,353; Kadi, 2008). It has both anabolic and androgenic properties; thus, it regulates 
the male sexual characteristics and influences muscle hypertrophy (Kadi, 2008). The 
leydig cells in testes are the main site of production in males. Another indirect site of 
production is the adrenal glands. The adrenal glands secrete the testosterone precursors 
dehydrorpiandrosterone and androstenedione (Chang, 2002, p.1-2,353).  Testosterone has 
many physiological benefits such as sexual development, overall health, immune 
function, muscle mass maintenance, and protection from osteoporosis (Chang, 2002, p.1-
2,353). Increasing testosterone levels aids in improving exercise performance, recovery, 
and appearance due to its anabolic activity on skeletal muscle (Kadi, 2008). Having said 
this, there are multiple mechanisms in which testosterone triggers skeletal muscle 
hypertrophy (See Figure 1). Testosterone may increase in the number of PCNA+ 
(proliferating cell nuclear antigenpositive) satellite cells in human skeletal muscle (Kadi, 
2008). In turn, these satellite cells mediate myotrophic action in response to testosterone 
(Kadi, 2008).  Other mechanisms initiating muscle hypertrophy via testosterone are 
myonuclear accretion and enhancement of myonuclei numbers (Kadi, 2008).  Not only 
that, but the activation of satellite cells via testosterone can lead to proliferation and 
differentiation into new myotubes (Kadi, 2008). Finally, testosterone has the capability to 
induce expression of myogenic markers in mesenchymal pluripotent cells, which favors 
them to differentiate into myocytes (Kadi, 2008) 
 
 
Figure 1: Testosterone mode of action on skeletal muscle (Kadi, 2008) 
 
A Brief Review of Benefits Associated With Dietary Supplements 
There have been numerous studies reporting benefits to dietary supplement use. 
An example of such would be creatine. Creatine’s ergogenic benefits are due to enhanced 
energy production in the muscle cells, thus it increases muscular power output (Kleiner, 
2007, p. 160-161). Not only does creatine enhance exercise performance, it also 
possesses therapeutic properties. In addition, Creatine improves skeletal muscle 
responses to exercise in chronic heart failure patients (Andrews et al., 1998). Another 
ergogenic aid with medicinal implications is Coenzyme Q10 (Ubiquinone).  Coenzyme 
Q10 has been recently shown to reduce exercise-induced muscular injury in athletes. In 
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addition, it increases aerobic exercise performance and has been shown to be a beneficial 
supplement to treat heart disease (Kleiner, 2007, p.124-125). 
Other notable dietary supplements that have been studied extensively with 
positive results include cinnamon extract, beta-alanine, and beta-hydroxy-beta-
methylbutyrate. Cinnamon extracts positively alter body composition due to their insulin 
modulation properties (Integrity, 2007). Also, cinnamon extracts moderately reduce 
glucose concentrations in diabetics (Mang et al., 2006).  
Beta-Alanine is an amino acid that is used by the body to synthesize carnosine, a 
dipeptide found in skeletal muscles. Enhanced carnosine levels in skeletal muscle tissue 
improve buffering H+ ions in muscle tissue (Kendrick et al., 2008; Harris et al., 2006). 
Therefore, it is suggested that carnosine may improve exercise performance (Parkhouse 
& McKenzie, 1984; Hill et al., 2007). Not only that, but carnosine can be used to treat 
various ailments due its antioxidant effects (Zeiba, 2007). Finally, research performed on 
Beta-hydroxy-beta-methylbutyrate, a metabolite of the amino acid leucine, suggests that 
it prevents muscle breakdown and helps in increasing muscle strength (Kleiner, 2007, 
p.169). Thus, beta-hydroxy-beta-methylbutyrate is not used only for ergogenic purposes, 
but also for therapeutic cases like muscle wasting diseases (Rathmacher et al., 2004).  
Testosterone Boosters 
A particular class of ergogenic aids referred to as testosterone enhancing dietary 
supplements are being marketed and sold nowadays. Testosterone is the major circulating 
sex steroid hormone in males. It is responsible for the development of secondary sexual 
characteristics including muscle growth via increased protein synthesis. Therefore, 
increasing testosterone levels is suggested to increase muscular hypertrophy. The premise 
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of increasing testosterone levels and its subsequent muscle growth stimulating properties 
has been illustrated in a study conducted by Bhasin et al. (2001). Bhasin et al. concluded 
that increased testosterone levels from an exogenous source improved muscle strength 
and mass in a dose dependent manner. Unfortunately, testosterone from exogenous 
sources is a controlled substance. Thus, nutritional supplement companies aim at 
producing products that aid the body in naturally producing more testosterone. These 
products are referred to as testosterone boosting supplements and are marketed as 
ergogenic aids. An example suggesting the efficacy of this class of ergogenic aids is 
discussed in a study entitled “Eight Weeks of Aromatase Inhibition Using the Nutritional 
Supplement Novedex XT: Effects in Young, Eugonadal Men” (Willoughby et al., 2007). This 
study has shown that Novedex XT supplementation has increased serum testosterone 
levels without any changes in clinical health markers, and reduced body fat (Willoughby 
et al., 2007).  This suggests that it is safe and an effective ergogenic product. 
Hormonal Responses to Resistance Training 
Resistance training is associated with significant elevations in anabolic hormones 
such as insulin-like growth factor-1 (IGF-1), growth hormone, and testosterone (Kraemer 
& Ratames, 2005). The elevations in these anabolic hormones are suggested to be 
responsible for the adaptive mechanisms in response to resistance training (Kraemer 
& Ratames, 2005). In particular, the increases in testosterone are in response to a single 
bout of resistance training. However, it seems that these elevations are transient and do 
not affect basal testosterone concentrations (Kraemer & Ratames, 2005).Thus, one of the 
purposes of this study is to investigate whether Mass FX increases basal testosterone 
concentration. 
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Mass FX™ 
This study will focus on Mass FX, a testosterone enhancing product that is 
manufactured by Anabolic Xtreme (Tempe, Arizona). The compounds found in this 
formulation pertain to two groups. According to the manufacturer, the first group of 
compounds are suggested to have anabolic activity and are composed of (3b, 5a, 6a, 
25R)-spirostan-3,6-diol (Chlorogenin), and (-)-3,4-divanillyltetrahydrofuran (DVTHF). 
Chlorogenin and DVTHF are plant extracts from the Chlorogalum pomeridianum 
(O’Neil et al., 2006) and Urtica dioica (Schöttner et al., 1997), respectively. The second 
group of compounds is included in the formulation to enhance the bioavailiabilty and 
absorption of the aforementioned anabolic compounds. These compounds are 6',7'-
Dihydroxybergamottin (6,7DHB) and Bioperine®. The compound 6,7DHB is extracted 
from grapefruit juice (Row et al., 2006); Bioperine® is extracted from black pepper 
(piper nigrum) (Sabinsa, 2005). All ingredients in this product are compliant with the 
Dietary Supplement Health and Education Act (DSHEA). They are not included on the 
current National Collegiate Athletic Association banned or controlled substances list. 
Thus, they are legal to obtain and consume under the DSHEA. 
Statement of Purpose 
The purpose of this study was to determine if Mass FX enhances performance and 
whether these improvements can be attributed to increase in testosterone concentration.  
Specifically, this study was conducted to: 
• Determine the efficacy of Mass FX™ on increasing total and free testosterone.  
• Determine the efficacy of Mass FX™ on improving body composition by 
increasing lean mass and decreasing fat mass. 
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• Determine the efficacy of Mass FX™ on increasing muscular strength.  
• Determine the effects of Mass FX™ on the selected clinical health markers (See 
Appendix F).   
Hypotheses 
In order to ascertain the effects of Mass FXTM on strength, testosterone, clinical 
health markers, and body composition, the following null hypotheses were identified. 
Ho1: Supplementation with Mass FX™ will not cause an improvement in body 
composition. 
Ho2: Supplementation with Mass FX™ will not cause an increase in total testosterone. 
Ho3: Supplementation with Mass FX™ will not cause an increase in free testosterone. 
Ho4: Supplementation with Mass FX™ will not cause an increase in muscular strength.  
Ho5: Supplementation with Mass FX™ will not cause a change in clinical health markers 
(See Appendix F).  
Operational Definitions 
The following are defined for this study. 
SHBG (Sex Hormone Binding Globulin): a glycoprotein that binds specifically to sex 
hormones such as testosterone. SHBG binds to testosterone with high affinity and 
subsequently attenuate the metabolic clearance of testosterone (Parker, 1993, p.1). 
Testosterone: is a steroid with anabolic and androgenic properties (Kadi, 2008). 
Nutritional ergogenic aids: refers to nutritional supplements that can enhance athletic 
performance (Antonio & Stout, 2001 p.15). 
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Dietary supplement: Under the DSHEA (Dietary Supplement Health and Education Act) 
of 1994, a dietary supplement is considered a  product taken orally that contains a 
"dietary ingredient" intended to supplement the diet. According to the U. S. Food and 
Drug Administration a dietary ingredient is: 
“The "dietary ingredients" in these products may include: vitamins, minerals, 
herbs or other botanicals, amino acids, and substances such as enzymes, organ 
tissues, glandulars, and metabolites. Dietary supplements can also be extracts or 
concentrates, and may be found in many forms such as tablets, capsules, softgels, 
gelcaps, liquids, or powders. They can also be in other forms, such as a bar, but if 
they are, information on their label must not represent the product as a 
conventional food or a sole item of a meal or diet. Whatever their form may be, 
DSHEA places dietary supplements in a special category under the general 
umbrella of "foods," not drugs, and requires that every supplement be labeled a 
dietary supplement”(U. S. Food and Drug Administration, 2001, para.1). 
Androgens: male sex hormones responsible for producing male characteristics. Major 
androgens include testosterone and its metabolite dihydrotestosterone. Androgens also 
include the testosterone precursors: dehydroeoiandrosterone and androstenedione (Chang, 
2002, p.1-2). 
Anabolic: refers to the physiological change that leads to an increase in lean muscle mass 
(Antonio & Stout, 2001, p.15).  
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Assumptions 
The following assumptions were considered for this study.   
1. Participants attended the training sessions as determined by the principle 
investigator. 
2. Participants performed only the exercises assigned to the study protocol. 
3. Participants followed dietary and supplement regimens throughout the study. 
4. Participants informed the principle investigator or assistants of failure to 
follow the accepted guidelines. 
5. All participants had similar active lifestyles, body types, and activities of daily 
life. 
6. Participants refrained from alcohol, sexual activity, intense physical activity, 
and exercise two days before pre and post trial testing.  
Significance 
The importance of this study was to determine the effects of Mass FX ™, a 
dietary supplement, touted to increase testosterone in adult males. Mass FX ™ contains a 
combination of ingredients that can be obtained from plant extracts: chlorogenin (a plant 
saponin from the California soap plant), (-)-3,4-divanillyltetrahydrofuran (an extract of 
the nettle root plant), bioperine (black pepper extract), and 6’,7’-dihydroxybergamottin 
(grapefruit extract).  
Previous studies performed on related plant extracts particularly saponins from 
the tribulus terrestris plant showed that were no significant increases in testosterone 
levels and exercise performance (Antonio et. al, 2000; Neychev & Mitev, 2005; 
Rogerson et al., 2007). In addition, studies performed on (-)-3,4-divanillyltetrahydrofuran 
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do not address the changes in  testosterone levels and exercise performance. Instead, 
studies performed on (-)-3,4-divanillyltetrahydrofuran focus on the compound’s 
capability to bind to sex hormone binding globulin (SHBG) (Schöttner et al., 1997; 
Schöttner et al., 1997; Schöttner et al., 1998) 
In this study, a new type of saponin, chlorogenin, was investigated with a 
combination of other compounds. Thus, the significance of this study was that it 
addresses the ergogenic effects of a combination of unique compounds that have yet to be 
studied in terms of ergogenic potential. However, since the product is comprised of 
multiple ingredients, it would not be possible to attribute any observed change to one 
compound only. Thus, this study aims at determining the ergogenic effects and clinical 
changes of Mass FX as a whole. 
Summary 
This chapter discussed the history and modern trends of using dietary 
supplements. In addition, it discussed the importance of researching supplements to 
obtain compelling scientific evidence in favor of these ergogenic aids. This would 
educate the consumer on these products and will help in preventing athletes from using 
illicit drugs and help them to chose and adhere to safe, moral, and healthy scientifically 
backed dietary supplements. Finally, this research project would study the efficacy of 
Mass FX™, a testosterone boosting supplement. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
This chapter will discuss the function of each ingredient of Mass FXTM. In 
addition, the function of testosterone and its effect on skeletal muscle will be discussed. 
Finally, this chapter will conclude with a summary.  
Mass FX™ Ingredients 
Touted Anabolic Compounds 
1. (3b, 5a, 6a, 25R)-spirostan-3,6-diol (Chlorogenin) 
Saponins are plant extracts with a sugar molecule bound to a steroid backbone. 
They have been used in traditional medicine in treatment of various disorders notably 
sexual impotence (Oshima & Gu, 2003). To validate this, in vivo studies have shown that 
saponins elevated testosterone levels significantly (Oshima & Gu, 2003), thereby 
suggesting a mechanism by which saponins induce their aphrodisiac effect.  Not only do 
Saponins have aphrodisiac properties, they are also used in reducing the incidences of 
angina pectoris (Wang et al., 1990). Such is the case with saponins extracted from 
Tribulus terrestris plant (Wang et al., 1990). Research performed on animal in vivo models 
has demonstrated enhanced testosterone production as a result of Tribulus terrestris 
administration (Gauthaman, 2002). However, studies conducted on adult human males 
have shown that Tribulus terrestris does not exert any testosterone boosting or 
performance enhancing effect (Antonio et. al, 2000; Neychev & Mitev, 2005; Rogerson 
et al., 2007). 
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Besides Tribulus terrestris, saponins are extracted from a variety of plant species. 
Mass FX™’s Chlorogenin is a non-sugar saponin obtained from the California soap 
plant. The plant is also known as Amole, (Chlorogalum pomeridianum) (Anderson & 
Roderick, 2006; O’Neil, et al., 2006). Chlorogenin has been shown to increase weight 
gain in rats (Syrov & Kurmukov, 1976). However, this anabolic effect was weakened 
when the rats were castrated (Syrov & Kurmukov, 1976). This suggests that chlorogenin 
might work by enhancing testosterone production on the level of the testes to produce 
such an anabolic effect (Syrov & Kurmukov, 1976). Thus, this mode of action suggests 
that chlorogenin is not an anabolic/androgenic steroid. If it were an anabolic steroid, its 
anabolic activity would not decrease because of castration. According to Syrov & 
Kurmukov (1976), chlorogenin displays anabolic activity without any androgenic 
properties. Thus, it can be hypothesized to be void of negative side effects associated 
with anabolic/androgenic steroids. With such anabolic properties, it is hypothesized that 
chlorogenin will help in enhancing testosterone production and probably the natural 
increase in testosterone production by the body in response to exercise. Therefore, the 
result of its usage might increase muscle mass and exercise performance due to increased 
protein synthesis in skeletal muscle tissue because of increased testosterone levels. 
2. (-)-3,4-divanillyltetrahydrofuran  (DVTHF) 
(-)-3,4-divanillyltetrahydrofuran  (DVTHF) is an extract from the stinging nettle 
root (Schöttner et al., 1997). DVTHF exerts its effects by acting on testosterone transport 
proteins. Testosterone in the human body exists either in a free circulating form or in 
inactive form bound to transport proteins. The transport proteins to which testosterone 
binds are albumin and sex hormone binding globulin (SHBG) (Neischlag et al., 2004). 
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DVTHF binds with very high affinity to SHBG (Ka = 3.2 +/- 1.7 x 10(6)M-1) (Schöttner 
et al., 1998). It is hypothesized that by binding to SHBG, DVTHF will increase the 
concentration of free testosterone. Due to the anabolic nature of testosterone, a higher 
concentration of free testosterone should translate into enhanced exercise performance 
manifested by an increase in muscle mass and strength. Also, it is hypothesized that 
DVTHF might positively influence body composition by increasing muscle mass and 
reducing body fat levels. This positive influence on muscle tissue is due to the higher rate 
of protein synthesis that occurs due to more availability of free testosterone binding to the 
androgen receptors on skeletal muscle tissue. Studies have shown that DVTHF binds to 
SHBG, however no studies have been conducted to show that more free testosterone will 
be available.  
Notable benefits associated with the plant in which DVTHF is extracted include 
effective treatment protocols for benign prostatic hyperplasia (BPH) (Schöttner et al., 
1997). Another benefit of Urtica dioica extracts is its blood glucose lowering effect. It 
has been used as a hypoglycemic for centuries in Persia as it has been noted in writings of 
Avicenna (981-1037), a prominent Persian medical scholar (Farzami et al., 2003).  Its 
therapeutic blood sugar balancing effects are a result of enhancement of insulin secretion 
by Islets of Langerhans (Farzami et. al., 2003) and by reduction of intestinal glucose 
absorption (Bnouham et. al., 2003). In addition to its hypoglycemic effects, Urtica dioica 
is used in traditional medicine to treat hypertension (Testai et al., 2002). Urtica dioica’s 
antihypertensive effects are attributed to vasorelaxing effects due to an upregulation of 
nitric oxide production in endothelial cells (Testai et al., 2002). Finally, Urtica dioica 
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exhibits antioxidant, antimicrobial, antiulcer, and analgesic properties (Gulcin et al., 
2004).  
Bioavailability and Absorption Enhancing Compounds 
1. 6',7'-Dihydroxybergamottin (6,7-DHB) 
The third ingredient is 6',7'-Dihydroxybergamottin (6,7-DHB). 6,7-DHB, a 
furanocoumarin, is one of the many bioactive compounds found in grapefruit juice (Row 
et al., 2006). 6,7 DHB has been shown to enhance the bioavailability of medications by 
inhibiting Cytochrome P3A4 (Ohta et al., 2002). Cytochrome P3A4 is an enzyme 
predominantly found in the liver that metabolizes various compounds such as drugs, 
xenobiotics, and endogenous compounds such as steroids (Robertson et al., 2003). It has 
been shown that the co-administration of 6,7DHB with a drug of interest will increase 
that drug’s concentration thus enhancing its effects (Christensen, 2002). Thus, according 
to the manufacturer, it is suggested that 6,7DHB might enhance the bioavailability of its 
anabolic ingredients.  
2. Bioperine® 
The final ingredient in Mass FX™ is Bioperine®. Bioperine® is a patented 
extract (US Patent# 5,536,506) from the black pepper plant. Bioperine® is used to 
increase the bioavailiabilty of nutritional compounds (Sabinsa, 2005). To illustrate this, 
clinical studies have shown that the co-administration of Bioperine® with coenzyme q10, 
beta carotene, and curcumin increased bioavailability by 30%, 60% and 2000% 
respectively (Badmaev et. al., 2000; Badmaev et al., 1999; Shoba et al., 1998). In Mass 
FX ™ and according to the manufacturer, the addition of Bioperine® is suggested to 
enhance the absorption of chlorogenin and DVTHF. 
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Potential Benefits 
Supplementation with Mass FX™ may provide a safe and natural alternative to 
illegal and unethical methods (Anabolic/Androgenic steroids) to enhance testosterone 
changes for athletes who train intensely and are at risk of overtraining.  
 
Muscle Hypertrophy 
The process of muscle hypertrophy is mediated by various genetic expressions of 
contractile and metabolic changes in muscle due to exercise (Borer, 2003, p.129). During 
exercise, the stretch of contractile proteins within skeletal muscles induces a cascade of 
transcriptional and translational growth signals including expression of myogenic 
regulatory factors and satellite cell proliferation, which in turn promotes hypertrophy by 
fusing with existing muscle fibers. Not only is muscle growth regulated process that 
induce muscular stretch, it is also induced by extra force loading such as weight training. 
Loading causes the down-regulation of a specific growth factor called myostatin. 
Myostatin is a inhibitor of muscle growth, thus its subsequent down-regulation due to 
exercise will result in a favorable environment for muscle growth (Borer, 2003, p.130).  
Finally, skeletal muscle hypertrophy can be induced by increases in testosterone levels 
(Borer, 2003, p.130). 
Testosterone and Resistance Training 
Testosterone concentrations change in response to acute and chronic training. 
Acute training responses refer to the responses that occur immediately after a single bout 
of exercise. On the other hand, chronic training responses refer to the responses that 
occur after progressive bouts of exercise over a specific period (i.e. weeks or months). 
Acute resistance training has been shown to cause a release of androgens including the 
17 
 
anabolic hormone testosterone, which persists for up to 20 minutes post a single bout of 
resistance training (Kraemer & Ratames, 2005). It has been suggested these acute 
responses appear to be vital in the muscle adaptive process that lead to tissue growth. 
Conversely, chronic training doesn’t increase basal testosterone concentrations (Kraemer 
 &  Ratamess, 2005). There are multiple hypotheses explaining the cause of these 
elevations. One explanation could be due to decreases in steroid metabolism in the liver 
due to reduced hepatic flow during exercise (Borer, 2003, p.168). Another explanation 
for increased testosterone levels may be attributed to the evidence showing that both 
testosterone and catecholamine concentration increases are directly proportional to 
exercise intensity. Thus, it has been hypothesized that sympathetic nerve activity and 
catecholamine release may induce testosterone elevations (Borer, 2003, p. 168). Further 
studies are required to confirm and elucidate these mechanisms in detail.  
Testosterone Mode of Action on Skeletal Muscle  
Sinha-Hikim et al. (2002) have shown that increases in muscle volume in 
response to graded testosterone levels was due to increases in muscle fiber type 1 and 2 
cross-sectional area, satellite cells and myonuclear number in a dose dependent fashion. 
In addition, testosterone supplementation in a nutrient deprived state stimulates synthesis 
of skeletal muscle proteins and reduces breakdown (Ferrando et al., 1998).  To illustrate 
the hypertrophic effects of testosterone, exogenous testosterone supplementation in 
healthy and diseased subjects resulted in anabolic activity including increases in strength 
and muscle mass (Bhasin et al., 1996; Bhasin et al., 2001; Knapp et al., 2008). 
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Summary 
This chapter discussed the Mass FX™ formulation with a detailed review 
regarding its ingredients. The possible potential benefits of this product were also 
discussed. Finally, this chapter concluded with a brief explanation of the muscle 
hypertrophy process, testosterone in relation to exercise, and testosterone’s influence on 
skeletal muscle.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
\ 
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CHAPTER III 
METHODS 
This chapter will discuss the overall hypothesis and methodology utilized for the 
study. This chapter will also discuss data gathering, recruiting, instrumentation, protocol 
procedures and design analysis. This chapter will be concluded by a summary of the 
methodology and protocols performed for the study. 
Overall Hypothesis 
It is hypothesized that the characteristic composition of Mass FX ™, a dietary 
supplement that enhances testosterone utilization, will improve muscular strength, body 
composition (increase in muscle mass), and free and total testosterone with no significant 
changes in selected clinical health markers (See appendix F).  
Setting 
This study was conducted at a university fitness center in a Mid-Western state.  
The university serves nearly 17,000 students, and offers more than 100 undergraduate 
and 50 Ph.D., graduate, and professional degrees. 
Human Subjects Consideration 
Human subjects have several rights when participating in a research study.  These 
rights include the right to self-determination, the right to privacy, the right to 
confidentiality, the right to fair treatment, and the right to protections from pain, 
discomfort, or other harm (Burns and Grove, 2004). 
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Subject Recruitment 
A sample of “apparently healthy" young males between 21-32 years of age from 
Wright State University were recruited to participate in the study. The participants were 
recruited by referral from employee’s at the local fitness center who discussed the study 
to regular patrons. If interested, volunteers were instructed to discuss the study further 
with the primary investigator (Mr. Patrick Dib). Participants who decided to be a part of 
the study were instructed to set up an initial screening appointment to determine their 
eligibility for the study at the Exercise Biology Laboratory at Wright State University. To 
be included in the study, subjects had to be young males aged 21-35 years of age with 
weight lifting experience of at least six months and with no current disease.  
Eligibility Determination 
To insure that the participants were “apparently healthy,” an AHA/ACSM 
Health/Fitness Facility Preparticipation Screening Questionnaire (Appendix A) was 
completed prior to engaging in this study.  
Participants who exhibited no more than one coronary artery disease risk factor 
and no signs/symptoms of metabolic, musculoskeletal, endocrine, or cardiopulmonary 
disease were considered apparently healthy in accordance with current American Heart 
Association / American College of Sports Medicine (ACSM) guidelines (ACSM, 2006, 
p.25). If warranted, subjects were asked to obtain medical clearance from their 
supervising physicians.  
Informed Consent 
The primary investigator (Mr. Patrick Dib) fully explained the procedures and 
methodology involved for the study. Mr. Dib also answered all questions that the 
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participants had after receiving approval from Wright State University’s Institutional 
Review Board. Furthermore, each subject who agreed to participate in the study 
voluntarily signed an informed consent (Appendix B). Before signing the consent, the 
subjects were informed that their participation was voluntary and that they reserve the 
right to withdraw at any time without any penalty.  
  Risks 
The following risks were noted for this study. 
1. Increased testosterone levels may cause acne, oily skin, increased body hair, 
minor hair shedding, and gynecomastia.  
2. Venipuncture may cause a slight bruise and minor pain. 
3. Although the study subjects will be well trained in muscular strength exercises, 
there may be some minimal muscle soreness 24 hours posttesting due to high 
subject motivation. 
4. Muscular injuries may result from training and testing. 
Randomization of Subjects 
After taking all the necessary pre-study measurements, subjects were divided 
randomly into two different groups using a web-based randomizer application 
(http://www.randomizer.org/).  The randomizer was utilized by an undergraduate 
assistant (UA). The UA assigned each subject a number from one to twelve in which was 
entered in the application. The UA set the application to output six random numbers from 
the 12 originally entered. The six numbers that were released designated group one, 
which represented the subjects who will supplement with Mass FX. The remaining six 
numbers belonged to group two which supplemented with the placebo. Both groups were 
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then given the protocol of supplementation, exercise, and diet. The supplements were 
distributed in a double blind manner. 
Subject Safety 
Subjects were monitored at every workout session by the primary investigator or 
trained and designated senior exercise biology student to ensure all safety precautions are 
followed. In addition, the subjects were contacted daily to determine problems or unusual 
symptoms that may arise.  
Subjects were all healthy and without any known current disease. They were not 
taking any other nutritional supplement, ergogenic aid, and/or drug. The only permitted 
supplement was pure whey protein powder containing no additional ingredients. This was 
done to ensure that the subjects met their protein requirements.   Subjects refrained from 
alcohol throughout the study.  
Exclusion Criteria 
The exclusion criteria included males younger than 21 years of age, with current 
medical disease, taking current medication, and/or with weight lifting experience of less 
than six months. In addition, any subject with significant anomalies observed during 
initial blood testing by the official medical supervisor, Dr. Corey Ellis and/or the primary 
investigator, Mr. Patrick Dib, were excluded. Finally, any subject who failed to comply 
with diet, nutrition, and/or supplementation were immediately withdrawn from the study.  
Diet 
Subjects’ total caloric intake and macronutrient breakdown was determined by 
incorpporating a diet utilized commonly by bodybuilders. Each subject had his own 
custom diet based on bodyweight.  First, baseline calories were determined for each 
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subject by multiplying his total body weight in pounds by 14. The number obtained was 
considered the baseline caloric intake in kcals. Then, 500 kcals was added to the baseline 
caloric value. This was done to ensure that subjects were consuming enough calories to 
promote exercise recovery and hypertrophy. The obtained total caloric intake was then 
distributed specifically amongst protein, carbohydrates, and fats.  
Protein intake in grams per day was determined by multiplying 1.2 to the body 
weight in pounds of the subject. Then, this value was multiplied by 4 to determine protein 
calories from the total calories that were calculated initially. 
Fat intake was set to be 25 % of total caloric intake. To determine the fat caloric 
amount in grams, the caloric value of fat was divided by 9.  
The calories that remained from subtracting the combination of protein and fat 
calories were those of carbohydrates. To determine the carbohydrate caloric amount in 
grams, the caloric value of carbohydrates was divided by 4 (See Appendix C). 
            Subjects were instructed to log their nutritional and supplement intake in a 
journal. Also, they were advised to use the USDA National Nutrient Database for 
Standard Reference website part of the department of agriculture to determine the caloric 
value of their meals (http://www.nal.usda.gov/fnic/foodcomp/search/) (Nutrient data 
laboratory, 2008). The subjects were instructed to provide the primary investigator with 
copies of the journal on a weekly basis to determine compliancy.  This enabled the 
primary investigator to review each log for each subject weekly. During the review, the 
primary investigator noted whether the subject was consuming the recommended calories 
and macronutrient recommendations. 
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Supplementation 
        To prevent observer bias, the study was conducted in a double-blind fashion. The 
primary investigator was not aware supplement distribution and group membership of 
each subject. Mass FX and placebo were administered to the subjects by the director of 
the exercise biology lab, Dr. Pohlman who kept the record of distribution. In addition, 
each subject was instructed to consume four pills/day as recommended by the 
manufacturer on the bottle regardless of bodyweight (See Appendix C). Both the actual 
supplement and placebo were provided by Anabolic Xtreme (Anabolic Xtreme, Tempe, 
AZ). Both pills were packaged exactly the same. They shared the same geletin capsule 
size, color, and outside labeling. Bottles were distinguished only by Dr. Pohlman via 
record of lot numbers. A certificate of analysis for the specific batch of Mass FX used in 
this study was provided to determine that the ingredients met with label claims. Placebo 
pills contained only rice flour and the gelatin from the capsule itself.  At the end of the 
trial, Dr. Pohlman provided the primary investigator with the record of distribution. In 
turn, this enabled the primary investigator to analyze the results with the appropriate 
statistical tests.  
Exercise Training Protocol 
All subjects followed the same resistance training protocol. The resistance 
training protocol used in this study was an upper/lower body split (See Appendix D) 
regimen with cardiovascular work on nonresistance training days. The subjects had only 
one full rest day during each week. The subjects performed the upper/lower training split 
twice a week with 48 hours in between each session. The rationale behind this frequent 
training is that there is evidence suggesting that there is a greater summation of myogenic 
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responses that might lead to better muscle hypertrophy responses (Haddad & Adams., 
2002). Not only that, but after a resistance training bout there are increases in muscle net 
protein balance for up to 48 hours (Phillips et al., 1997). Therefore, it is hypothesized that 
the frequent training (48 hours between sessions during a week) in this study might 
further enhance the muscle net protein balance increases, which might subsequently lead 
to better muscle hypertrophy. In addition to resistance training, endurance training was 
performed to enhance insulin sensitivity via upregulation of the glucose transporter 
protein, GLUT-4 (Hardin et al., 1995). Subjects performed 30 minutes of low intensity 
endurance training. This was done in efforts to improve nutrient partitioning towards 
muscle tissue. 
Pretesting 
Demographics and Anthropometric Measurements 
After signing the informed consent, demographic information regarding each 
subject was collected. This information included the subject’s name, date of birth, height, 
weight and body fat (Appendix E). In addition, each subject was assigned an ID number, 
which was used during result analysis to maintain confidentiality of subject data.  
Stature was measured without shoes and socks to the nearest 0.1 inch using a 
stadiometer (SECA, 2006, Germany). Prior to taking the measurement, it was assured 
that the individual’s weight was equally distributed through both feet with heels together 
and arms at the sides of the trunk. The subjects were instructed to keep their heads in 
level with the eyes fixed straight ahead in a Frankfort plane position. 
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Body Composition 
Body fat and weight was measured via a recently calibrated BOD/POD (Life 
Measurement Inc., Concord, CA). To do so, the subjects wore spandex or compression 
shorts and removed all jewelry and accessories. In addition, the subjects were given a 
Speedo© head cap to cover their hair. This is done in order to make sure that no air is 
trapped in the hair. Also, the subjects refrained from eating, drinking, and exercising for 2 
hours before the test. 
The BOD/POD utilizes air displacement to produce its results. It is a very 
convenient way of assessing body composition in comparison to other techniques such as 
skin fold calipers, bioelectrical impedance, hydrostatic weighing, and DEXA (Duel 
Energy X-Ray Absorptiometry) for various reasons. First, it is very user friendly: the 
subject sits in relaxed manner inside the machine; the procedure doesn’t involve exhaling 
air out of the lungs underwater (compared to hydrostatic weighing) and it doesn’t involve 
radiation (compared to DEXA). Secondly, it has a much lower error rate (+2%) (Life 
Measurement Inc., 2006). Other methods, such as BIA and skinfold calipers, may have a 
6-8% error range (Life Measurement Inc., 2006). Finally, it reproduces results in a time 
efficient fashion, usually 5-8 minutes with minimum disturbances to the subject. Skin 
pinching, holding the breath, pressing buttons, and radiation exposure are not an issue 
with a BOD/POD. 
Blood Chemistries 
After gathering demographic and body composition data, blood samples were 
drawn to analyze blood chemistries prior to the start of study. Blood was drawn by a 
certified phlebotomist from LabCorp (Laboratory Corporation of America, 3291 Seajay 
Dr, Beavercreek, OH 45430). Serum testosterone concentrations exhibit diurnal variation 
(Diver et al., 2003) (See Figure 2). Studies have shown that testosterone concentrations 
peak in the morning at 0700hrs (Walton et al., 2007) reaching their lowest concentration 
in the early evening at 1900 h (Walton et al., 2007). Due to these findings, the blood tests 
were performed first thing in the morning after an overnight fast of 12 hours. This was 
performed in order to determine the testosterone concentrations at its peak concentrations 
and for consistency in measurements.  
 
Figure 2: Diurnal variation in testosterone concentrations (Diver et al., 2003). 
 
 In addition, subjects refrained from alcohol, sexual activity, intense physical 
activity, OTC medications, and exercise two days before the blood draw. The 
phlebotomist took approximately three vials of blood from the antecubital vein. Then, the 
samples were subsequently analyzed by LabCorp for the following markers: 
1. Complete blood count:  white blood cell count (WBC),  white blood cell 
differential: (neutrophils lymphocytes, monocytes, eosinophils, basophils,), 
absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute 
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eosinophils, absolute basophils, red blood cell count (RBC), hemoglobin (Hb), 
hematocrit (Hct), platelet count, mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration 
(MCHC), red cell distribution width (RDW). 
2. Lipid Profile:  Low density lipoprotein (LDL), High density lipoprotein (HDL) , 
Very low density Lipoprotein (VLDL), Triglycerides (TG), Total cholesterol 
(TC).  
3. Hepatic:  Alkaline phosphatase (ALP),  Aspartate aminotransferase (AST), 
Alanine aminotransferase (ALT) 
4. Renal:  Creatinine, Blood Urea nitrogen (BUN) 
5. Serum Steroids:  Total and free testosterone.   
Total and free testosterone analyses are usually performed to determine gonadol 
function (Bishop et al., 2005, pg 438). In this study, these tests will determine if Mass FX 
enhances testosterone production in the body. Free testosterone measurement refers to the 
measure of testosterone that is not bound to any transport proteins (Bhasin et al., 1998). 
Total testosterone measurement refers to the measure of free plus protein bound 
testosterone. 
The liver enzymes alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) are measured to determine if there are any hepatic complications. 
Elevations in both AST and ALT indicate hepatocellular injury (Gail, 1999, p. 178). 
Alkaline phosphatase is measured to determine if there is any bile flow impairment, 
development of space occupying lesions, cholestasis, and other conditions including but 
not limited to viral hepatitis and hepatic lipidosis. (Gail, 1999, p. 182). The renal marker, 
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creatinine, is tested to determine any renal complications such as decreased glomerular 
filtration rate. It is also tested to determine any skeletal muscle myopathy (Gail, 1999, p. 
59). The second renal marker, blood urea nitrogen (BUN), is usually tested to determine 
if there is any chronic glomerulonephritis, pyelonephritis, and other chronic kidney 
diseases (Gail, 1999, p. 60).  Complete blood count with differential analysis is usually 
performed to detect anemia, evaluation of inflammation, infections and peripheral blood 
characteristics, and polycythemia evaluation (Gail, 1999, p. 71). In the blood complete 
blood count analysis, the red blood cell indices, RDW (Red cell distribution width), MCV 
(Mean corpuscular volume), MCH (Mean corpuscular hemoglobin), and MCHC (Mean 
corpuscular hemoglobin concentration were studied.  Briefly, MCV denotes the size or 
volume of the erythrocyte. MCH denotes the weight of the hemoglobin in the average 
erythrocyte. MCHC refers to the amount of hemoglobin present in the average red cell as 
compared to its size. Finally, RDW refers to erythrocyte size variability (Jacobs et al., 
1996, p. 344).  Measuring red blood cell indices offer a quick and efficient method to 
determine hematological abnormalities such as anemia, iron deficiency, spherocytosis 
(sphere-shaped erythrocytes), folate deficiency, vitamin B12 deficiency, vitamin B6 
deficiency, and thalassemia (Jacobs et al., 1996, p. 343). As for immune function, the 
absolute and percentage number of leuckocytes were measured. Absolute values denote 
the absolute count of the leukocytes: neutrophils, lymphocytes, monocytes, eosinophils, 
and basophils, respectively. The absolute counts are calculated by multiplying the 
percentage of each type of leukocyte by the total white blood cell count. Finally, lipid 
profile analysis measures total cholesterol, low density lipoproteins, and high density 
lipoproteins to evaluate cardiovascular risk factors (Bishop et al., 2005 p.282). 
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Muscle Strength Testing 
The subjects were instructed to return to the Exercise Biology laboratory two days 
after the blood sampling to determine their muscular strength. Prior to assessing 
performance, the subjects were asked to warm-up for 10 minutes by performing light 
aerobic activity (fast walking on a treadmill) and dynamic stretches. After warming up, 
the subjects performed the three designated lifts required for the study: bench press, 
deadlift, and leg press.  
Each activity is unique because each lift tests different muscle groups and 
different muscular skills. The rationale behind using three different exercises instead of 
one is because there is no single known exercise that tests for whole body strength. 
Instead, testing via a variety of exercises that focus on one area of the body at a time will 
produce accurate results in determining exercise performance improvements.  
The first lift performed was the bench press. The bench press is a lift that focuses 
on upper body strength since it predominantly utilizes the pectoralis major, anterior 
deltoid, and the triceps to perform work (Aaberg, 1999 p.154).  
The second lift is the deadlift. The deadlift can be considered as an exercise that 
utilizes both upper body and lower body muscles manifest by utilization of the leg muscle 
as well as the abdominals (core muscles) trapezius, and the rhomboids (upper back 
muscles). The deadlift is considered one of the best exercises for body strength (Groves, 
2000 p.41). Along with the bench press, it is included in powerlifting competitions 
(Groves, 2000 p.31, 41).  
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The third and final exercise is the leg press. The leg press test is a measure of 
lower body strength. The muscle fibers that are recruited to perform the work are the 
gluteus maximus and minimus, hamstrings, and the quadriceps. It is a very efficient and 
safe exercise since it stabilizes the body in a fixed position thus reducing the risk of back 
and spinal injury in comparison to other compound leg exercises such as the squat 
(Aaberg, 1999 p.130). 
All these lifts were performed in a 1 Repetition Maximum (1-RM) manner. 1-RM 
tests are performed in a gradual fashion with added weight on each trial until the subject 
cannot perform a complete lift. Each subject initially started with a low weight. If the 
subjects can perform the lift properly, five pounds were added to the next attempted lift. 
This continued until the subject could no longer lift the specified amount of weight. The 
last amount of weight used in which the subject performed a complete full repetition was 
considered their one repetition maximum. During these tests, a spotter was available to 
minimize the risk of injury and to ensure the proper execution of the exercises. The 
spotter only helped when the weight was moving down towards (down) the subject, not 
when moving away (up).  
Posttesting 
After the successful completion of the allocated six week study, the pre-testing 
measurements: body composition, blood chemistries, and muscular strength were 
repeated in order to determine any changes that may have occurred as a result of 
supplementation.   
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Design and Analysis 
The design of the study was of a Pretest-Posttest Control group design. The 
experimental and control groups were randomly assigned. To prevent observer bias, the 
study was conducted in a double-blind fashion. The primary investigator was not aware 
of the distribution of supplements and or group membership. The supplements and 
placebo were administered to the subjects by Dr. Pohlman who kept the record of 
distribution. In addition, the subjects were instructed to consume 4 pills/day (See 
Appendix C). Both the actual supplement and placebo were provided by Anabolic 
Xtreme. Both pills were packaged exactly the same. They shared the same pill size, color, 
and outside labeling. Bottles were distinguished only by Dr. Pohlman via record of lot 
numbers. 
All statistical analyses were performed at Wright State University’s statistical 
consultation center. Results were analyzed by Analysis of Covariance (ANCOVA), using 
Group as the independent binary variable (binary value having 2 levels: Mass FX™ 
[MFX] or Placebo [P] and the corresponding pre-treatment variable as the covariate.  Due 
to the number of variables, the ANCOVA with a Bonferroni correction was initiated 
resulting in a family-wise level of significance of α = 0.05, to avoid inflation of the Type 
I error. To confirm results, an independent samples t-test using a Bonferroni correction 
with a family-wise level of significance of α=0.05 was performed. 
Summary 
This chapter described the methods that were used in this study. A sample of 
“apparently healthy” young males was recruited through learning about the study at the 
university’s local fitness center. Demographics were taken first, followed by other study-
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specific measurements (body composition, 1-RM muscle strength, and blood 
chemistries). After obtaining the required measurements, the subjects received the 
supplements and placebo depending on the group to which they were randomly assigned. 
A workout program was provided and used in conjunction with the supplementation for 
six weeks. After six weeks, the subjects were retested again to determine any changes in 
body composition, exercise performance, and blood chemistries. All data gathered from 
the pre- and posttrial testing dates were recorded and analyzed to determine significant 
changes in  the aforementioned variables due to supplementation with Mass FX.  
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CHAPTER IV 
The aim of this chapter is to present all the data gathered in this trial. In addition, 
this chapter will reveal the statistical analysis performed to draw conclusions based on 
the hypotheses presented in Chapter I.  Finally, this chapter will end with a summary of 
the major findings in this trial. 
Results 
The subjects’ mean age was 25 + 3.02 years. Their mean height was 70 inches + 
3.07 (177.8 centimeters + 7.79). Their body weight before and after the trial was 186.17 
pounds + 28.13 (84.23 kilograms + 12.72) and 187.38 pounds + 30.16 (84.78 kilograms + 
13.64), respectively.   All eight subjects had at least two years of weight training 
experience. They completed the trial successfully with full compliance to testing, diet, 
training, and supplementation. The subjects kept records of diet and supplementation and 
shared them with the primary investigator each week 
The study started with six adult males in each of the treatment and control groups, 
but four of the participants failed to follow the study guidelines and were omitted from 
the final analyses. Four participants in each group remained. 
To analyze the results, the data from both groups were separated into two 
categories: Primary outcomes and Secondary outcomes. The Primary outcomes data set 
included total and free testosterone, bench press, deadlift, leg press, fat mass, and fat free 
mass values. The Secondary outcome data set included the selected clinical health 
markers. (See Appendix F). All analyses were conducted using statistical software 
package SPSS 16.0.  
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Primary and Secondary outcomes were analyzed by Analysis of Covariance 
(ANCOVA), using Group as the independent binary variable and the corresponding pre-
treatment variable as the covariate. Specifically, the Group variable represents group 
membership to either Mass FX or Placebo. On the other hand, the pretreatment variable 
represents the initial values to the parameters being studied prior to exercise and 
supplementation with either Mass FX or Placebo.  Because of the multiple hypotheses 
being tested, a Bonferroni correction with a family-wise level of significance of α = 0.05, 
was used when determining which ANCOVAs were significant in each family of tests.  
To confirm results, an independent samples t-test using a Bonferroni correction with a 
family-wise level of significance of α=0.05 was performed 
Method of Analysis 
Using ANCOVA the Post-value was modeled on group and pre-treatment values. 
This was done to determine if Group affects the post value after adjusting for the Pre-
value.  Using the independent samples t-test, the outcome was modeled to be the 
difference between pre and post values. 
Primary Outcomes 
The variables of Group and the corresponding Pre-treatment measure were not 
sufficient (p>0.05) to explain the variance in outcomes for total testosterone and free 
testosterone (See Table 20). In this case, statistical conclusions can not be made.  On the 
other hand, the other five ANCOVA models run (bench press, deadlift, leg press, fat 
mass, and fat free mass values) were significant and warranted further examination (See 
Table 20).  For all five of these models, the pretreatment variable was significant 
(p<0.05), indicating that it was useful to include it as a covariate (See Table 20). 
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After adjusting for pretest bench press values, the two study groups showed a 
statistically significant difference in the mean bench press weight (p=0.019). The mean of 
the Mass FX group (mean = 15.27 kilograms) was greater than the Placebo (mean= 1.69 
kilograms).  Therefore, the Mass FX group, on average, was lifting statistically 
significantly heavier weights than their placebo counterparts were. Group membership 
was not significant for Leg Press, Dead Lift, Fat Free, and Fat Mass. This suggests that 
for these variables associated with Primary outcomes most of the variance was due to the 
pretreatment variables (p<0.05) and not the group variable (p>0.05). In this case, it is 
suggested that exercise, not supplementation was a major factor in explaining the 
variance of these outcomes. In detail the findings of the primary outcomes were: 
• Bench press – the model was significant (p = 0.000), and the adjusted R2 = 0.966 
suggests that the variables Group and Pre-bench explain about 96% of the 
variation in the outcome Post-bench.  The Group membership variable was 
significant in this case (p = 0.019).  The estimate of the beta coefficient = -32.323.  
This means that the mean value of the Bench Press outcome was on average about 
32 pounds (or 14.65 kilograms) lower for the Placebo group when compared with 
the Mass FX treatment group, after adjusting for weight that was bench-pressed 
prior to the intervention. 
• Leg press – the model was significant (p = 0.000), and the adjusted R2 = 0.942 
suggests that the variables Group and Pre-Leg explain about 94% of the variation 
in the outcome Post-Leg.  The group variable was not significant (p = 0.134).  
• Deadlift – the model was significant (p = 0.000), and the adjusted R2 = 0.934 
suggests that the variables Group and Pre-deadlift explain about 93% of the 
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variation in the outcome Post-deadlift.  The group variable was not significant (p 
= 0.284).  
• Fat free mass– the model was significant (p = 0.000), and the adjusted R2 = 0.991 
suggests that the variables Group and Pre-fat free mass explain about 99% of the 
variation in the outcome Post-fat free mass.  The group variable was not 
significant (p = 0.215).  
• Fat mass – the model was significant (p = 0.000) and the adjusted R2 = 0.972 
suggests that the variables Group and Pre-fat mass explain about 97% of the 
variation in the outcome Post-fat mass.  The group variable was not significant (p 
= 0.955).  
Secondary Outcomes 
The remaining variables, the secondary outcomes (See table 21), were of interest 
only in verifying that there was no change from pre- to posttraining for these measures.  
The same type of model (ANCOVA) was used for these variables as for the primary 
variables of interest.   
In all secondary outcomes, the outcome was not significantly affected by the 
Group variable (all p>0.05) (See Table 21). Therefore, it is suggested that 
supplementation does not affect these health markers.  
It was noted that the ALP and Platelet count outcome models were significant at 
the family-wise level of significance α = 0.05 using a Bonferroni correction at the Pre-
treatment variable level (See Table 21),  but any changes were considered due to changes 
from pre-treatment values and not due to supplementation (Group variable p>0.05). 
However, despite changes, all values remained within the normal ranges.  
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Strength Test 
As mentioned earlier, both groups had significant improvements in all three 
strength tests (Model significance p<0.05) However, the bench press outcome had a 
group variable of p<0.05 suggesting that Mass FX supplementation had a role in this 
improvement. 
To reiterate, all subjects using Mass FX showed strength improvements in all 
three lifts in comparison to their pre-trial values. Of all three strength parameters, only 
the bench press differences were statistically significant between the two groups (See 
Table 1). The Mass FX group exhibited a mean increase of 15.27 kilograms between pre- 
and post test whereas the Placebo’s mean difference increase was 1.69 kilograms from 
pre-trial testing (See Figure 3). The percent difference between both groups was 
calculated to be 800 %.  For the deadlift, the Mass FX group exhibited a mean difference 
increase of 15.8 kilograms whereas the Placebos mean increase was 7.91 kilograms (See 
Figure 4). The deadlift percent difference between both groups was calculated to be 100 
%.  Finally, for the leg press, the mean increase was 48.07 kilograms for Mass FX 
whereas the change in Placebo was 13.57 kilograms (See Figure 5). The leg press percent 
difference between both groups was calculated to be 254.16 %. 
 
 
 
 
 
 
Table 1 
Muscle Strength for Mass FX Group (kg) a 
Subject   Bench Press  Leg Press      Deadlift 
    Pre         Post  Pre           Post      Pre          Post 
MFX1     110.85  124.43   348.41   409.50     142.53   156.10            
MFX2    117.64   142.53   470.58    552.03   183.25   205.88   
MFX3    119.90   128.95   429.86    452.48   165.15   174.20 
MFX4    110.85   124.43   429.86   457.01    138.00   156.10 
Mean    114.81   130.09   419.68   467.76   157.23   173.07 
S.D    4.66        8.56        51.24     60.12     21.02      23.47 
a Notes: Comparison of Mass FX pre/post results of the 1‐RM max test 
 
Table 2 
Muscle Strength for Placebo Group (kgs) a 
Subject   Bench Press  Leg Press        Deadlift 
    Pre      Post  Pre           Post        Pre           Post 
PL1    88.23    88.23   266.96     266.96      124.43    124.43 
PL2    138.00  138.00  429.86     429.86      151.58    165.15 
PL3    56.56     61.08  257.91     289.59      83.71      101.80 
PL4    88.23     90.49  266.96     289.59      124.43    124.43 
Mean    92.76   94.45      305.42    319.00     121.04    128.95 
S.D    33.65   31.96      83.06       74.67       27.98      26.38 
a Notes: Comparison of Placebo pre/post Results of the 1‐RM max test   
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Figure 3: Comparison of mean Bench Press changes between Mass FX and Placebo.  
*p=0.019 
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Figure 4:Comparison of mean Deadlift changes between Mass FX and Placebo. 
 
40 
 
Post Trial Leg Press Changes
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Figure 5: Comparison of mean Leg Press changes between Mass FX and Placebo. 
 
 
Body Composition 
Significant improvements in body composition were reported in both Mass FX 
and Placebo groups (Model significance p<0.05). However, the Mass FX group exhibited 
better improvements (Table 3); yet, these changes could not be attributed to 
supplementation (Group significance p>0.05). Mass FX’s mean lean mass (fat free mass) 
increase was 2.26 kilograms, whereas the Placebo subjects mean increase was 0.98 
kilograms (See Figure 6). The percent difference between the groups was calculated to be 
134.48 %.  Regarding fat mass, Mass FX had a small improvement over the Placebo 
group. Mass FX had a mean reduction of 1.09 kilograms of body fat while the placebo 
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had a mean reduction of 1.05 (See Figure 7). The percent difference of this parameter 
between Mass FX and Placebo was calculated to be 4.301 %.  
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Figure 6: Comparison of mean Fat Free Mass gains between Mass FX and Placebo 
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Figure 7: Comparison of mean Fat Mass loss between Mass FX and Placebo 
Table 3 
Body Composition Changes a  
Subject    Fat Free Mass  (kgs)      Fat Mass (kgs) 
Pre   Post        Pre   Post 
MFX1      73.30 76.06    9.00  8.95 
MFX2   76.19 80.18     25.42 24.34 
MFX3   73.07 74.38    10.22 8.95 
MFX4   70.04 71.04    17.10 15.11 
Mean   73.15 75.41    15.44 14.34 
S.D   2.51 3.80    7.55 7.27 
PL1   59.32  59.72     27.28  28.95 
PL2               80.63  82.03     15.61 14.38 
PL3               44.66 46.28     14.66 12.76 
PL4   69.18 69.68    8.05  5.29 
Mean      63.45  64.43        16.40  15.35 
S.D      15.25  15.15         7.99  9.89 
a Notes: Pre‐ and post‐changes in fat free mass and fat mass in Mass FX (MFX) and Placebo (PL) 
groups 
43 
 
Renal Function 
Renal function was assessed by testing for creatinine and blood urea nitrogen 
(BUN) levels (Tables 4 and 5).Unlike BUN, creatinine exhibited a Model p value <0.05. 
However, it was not considered a significant model after applying the Bonferroni 
correction. Supplementation with Mass FX did not affect these markers (Group variable 
p>0.05).  
 
Table 4 
Renal Values for Mass FX Group (mg/dl) a 
Subject   Creatinine    BUN 
    Pre  Post    Pre  Post 
MFX1    1.1  1.2    21  22 
MFX2    1.1  1    19  12 
MFX3    1.1  1.3    25  18 
MFX4    0.8  0.7    21  15 
Mean     1.025    1.05      21.5     16.75 
S.D    0.15  0.26    2.51  4.27 
a Notes: Comparison of Mass FX pre/post Results of renal function test. Reference ranges for Creatinine 
are 0.5‐1.4 mg/dl. Reference ranges for BUN are 3‐29 mg/dl. Ranges provided by Compunet Labs 
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Table 5 
Renal Values for Placebo Group (mg/dl) a 
Subject   Creatinine    BUN 
    Pre  Post    Pre  Post 
PL1    1  1.1    14  19   
PL2    1.3  1.2    15  17 
PL3    0.8  0.8    15  20   
PL4    1.1  1.1    16  20 
Mean    1.05  15    1.05  19 
S.D    0.20  0.81    0.17  1.41 
a Notes: Comparison of placebo pre/post results of renal function test. Reference ranges for 
Creatinine are 0.5‐1.4 mg/dl. Reference ranges for BUN are 3‐29 mg/dl. Ranges provided by 
Compunet Labs 
 
Serum Steroids 
As mentioned earlier, the variables of group and the corresponding pretreatment 
measure were not sufficient to explain the variance in outcomes for total testosterone 
(p=0.619) and free testosterone (p=0.076). In this case, statistical conclusions can not be 
made. However, improvements were observed, as it was apparent that the Mass FX group 
had higher free testosterone levels than recorded at initial testing. In, addition, the 
Placebo’s free testosterone levels decreased from pre- to post-testing trial measurements.  
For total testosterone, the Mass FX group exhibited a mean increase of 98.75 
ng/dl between pre- and posttesting. On the other hand, the placebo group exhibited a 
mean decrease of - 189.5 ng/dl from pretrial testing (see Figure 8).  
For free testosterone levels, the Mass FX group exhibited a mean increase of 
46.35 pg/ml between pre- and posttesting. Surprisingly, the Placebo group exhibited a 
mean decrease of -41.1pg/ml from pretrial testing in free testosterone concentrations (See 
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Figure 9). Despite the differences from pre- to posttesting in both groups for total and 
free testosterone, values remained within the reference ranges (See Tables 6 and 7). 
The results of the independent sample t test suggested that there are statistically 
significant differences for the free testosterone outcome between the two groups 
(p=0.001) 
 
Table 6 
Serum Steroids for Mass FX Group a 
Subject   Total Test (ng/dl)  Free Test (pg/ml) 
    Pre      Post    Pre      Post 
MFX1    222      484    43.7     115.2 
MFX2    461      448    94.1      148.5     
MFX3    372      546    75.6      109.7 
MFX4    424      396    75.9      101.3 
Mean    369.75   468.5      72.32  118.67 
S.D                105.04  63.04231            20.95   20.68 
a Notes: Comparison for Mass FX pre/post results on serum steroids. Reference ranges provided by 
compunet: total testosterone: 250‐1100 ng/dl; free testosterone: 35‐155 pg/ml 
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Table 7 
Serum Steroids for Placebo Group a 
Subject   Total Test (ng/dl)  Free Test (pg/ml) 
    Pre       Post    Pre       Post 
PL1    507       339    128       87.4     
PL2    497       503    109       91 
PL3    664       534    181.1    115.1      
PL4    1024     558    126        86.2 
Mean    673     483.5    136.02   94.92     
S.D    246.18   98.92    31.23    13.60 
a Notes: Comparison for placebo pre/post results on serum steroids. Reference ranges provided by 
compunet: total testosterone: 250‐1100 ng/dl; free testosterone: 35‐155 pg/ml 
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Figure 8: Comparison of mean changes in Total Testosterone between Mass FX and Placebo. 
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Figure 9:Comparison of mean changes in Free Testosterone between Mass FX and Placebo.  
*: p=0.001 
 
 
Hepatic Function 
Hepatic function was assessed by testing for alkaline phosphatase (ALP), 
Aspartate transaminase (AST) and alanine transaminase (ALT). All markers remained 
within the reference ranges except for one subject (MFX2) who had an elevated 
pretesting value for both AST and ALT that was also observed in post-testing (See Tables 
8 and 9). Hence, this anomaly was independent of supplementation. A model p value of 
<0.05 was observed for all hepatic markers AST, ALT, and ALP. However, the changes 
in ALT and AST were not considered significant models after applying the Bonferroni 
correction. Both ALT and AST values remained within the normal ranges except for 
(MFX2). On the other hand, the ALP changes were considered significant at the family-
wise level of significance α = 0.05 using a Bonferroni correction at the pretreatment 
variable level. Despite these significant changes, the ALP values remained within the 
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reference ranges and are not attributed to supplementation (Group variable p>0.05). This 
change is not attributed to Mass FX supplementation (Group variable p>0.05), but is due 
to changes from pre-treatment values. In addition, Mass FX did not affect ALT and AST 
values (Group variables p>0.05). 
 
 
 
 
Table 8 
Hepatic Values for Mass FX Group (U/L)a 
Subject   ALP    AST    ALT 
    Pre     Post  Pre     Post  Pre     Post 
MFX1    77       73  28       32  28       29 
MFX2    101     87  28       21  47       24   
MFX3    58       66  50b   53b  92 b  109b 
MFX4    70       69  35       28  42       37 
Mean    76.5    73.75  35.25 33.5    52.25  49.75   
S.D    18.11  9.28  10.37 13.77  27.69  39.86   
aNotes: Comparison for Mass FX pre/post results on Hepatic enzymes .Reference ranges for ALP, AST, and 
ALT are 23‐144 U/L, 0‐46 U/L, and 0‐60 U/L, respectively. Ranges provided by Compunet Labs.  
belevated 
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Table 9 
Hepatic Values for Placebo Group (U/L)a 
Subject   ALP    AST    ALT 
    Pre     Post  Pre     Post  Pre     Post 
PL1    47      44  20      20  24      24 
PL2    65      66  30      24  31      31 
PL3    134    119  28      27   34     26 
PL4    102    109  32      34  27      30 
Mean    87       84.5  27.5   26.25         29      27.75 
S.D    38.80 35.46       5.25    5.90           4.39   3.30 
aNotes: Comparison for placebo pre/post results on hepatic enzymes. Reference ranges for ALP, AST, and 
ALT are 23‐144 U/L, 0‐46 U/L, and 0‐60 U/L, respectively. Ranges provided by Compunet Labs.  
 
 
Lipid Profiles 
Lipid profiles were assessed by testing for LDL, HDL, VLDL, triglycerides, and 
total cholesterol (See Tables 10 and 11). LDL, HDL, and total cholesterol showed a 
model p value of <0.05. However, they were not considered significant models after 
applying the Bonferroni correction. Mass FX supplementation did not affect any of lipid 
markers (Group variable p>0.05). 
It is worth mentioning that both LDL and HDL values fluctuated minimally in 
some subjects. This could be due to diet and/or exercise as these values are often 
influenced by them. Most subjects had less than optimal HDL levels during initial testing 
which was also apparent during posttesting; thus, it was independent of supplementation. 
There were no adverse changes in the Mass FX group on any of these lipid markers. One 
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subject in the Placebo group (PL1) showed elevated LDL values during pre- and 
posttesting, while another subject (PL2) had elevated LDL levels posttesting – a possible 
cause could be diet. 
 
Table 10 
Lipid Profiles for Mass FX Group (mg/dl)a 
Subject   LDL    HDL    VLDL    Triglycerides    Total C 
    Pre   Post  Pre   Post  Pre   Post  Pre   Post  Pre      Post 
MFX1    69     66   45       40  8       18     42      92  122      124 
MFX2    73     69   57       46  16     8    82      41  146      123 
MFX3    76     69   37       45  12     13   60      63  125      127 
MFX4    85     79   58       53  7       8    36      41  150      140 
Mean    75.5  70.75  49.25 46  10.75 11.75  55       59.25  135.75  128.5 
S.D    6.80  5.67  10.07 5.35  4.11    4.78  20.68 24.17  14.29     7.85 
 
a Note: Comparison for Mass FX pre/post results on lipid profiles. Reference ranges as provided 
by Compunet: Triglycerides<150 mg/dl; total C <200 mg.dl; VLDL= 4‐28 mg/dl; LDL <100, HDL 
>60 mg/dl.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
Table 11 
Lipid Profiles for Placebo Group (mg/dl) 
Subject   LDL    HDL    VLDL    Triglycerides  Total C 
    Pre   Post  Pre   Post  Pre   Post  Pre   Post  Pre   Post 
PL1    126b     128 b  44       46  25      18  126    90  195   193 
PL2    91       110 b  27       29  19      19  93      96  137   158 
PL3    94       75   42       36      16      19  82      94  152   130 
PL4    55       65  61       69  9         9   45       47  125    143 
Mean    91.5    94.5  43.5    45  17.25 16.25  86.5   81.75  152.25 155.75 
S.D    29.03 29.51  13.91 17.45  6.65    4.85  33.39 23.30  30.65   26.73 
a Note: Comparison for Mass FX™ pre/post results on lipid profiles. Reference ranges as 
provided by Compunet: Triglycerides<150 mg/dl; total C <200 mg.dl; VLDL= 4‐28 mg/dl; LDL 
<100, HDL >60 mg/dl.  
b elevated 
 
Complete Blood Count  
Whole blood analysis was assessed by testing for white blood cell count (WBC), 
white blood cell differential (neutrophils lymphocytes, monocytes, eosinophils, and 
basophils), absolute neutrophils, absolute lymphocytes, absolute monocytes, absolute 
eosinophils, absolute basophils. red blood cell count (RBC), hemoglobin, hematocrit, 
platelet count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), 
mean corpuscular hemoglobin concentration (MCHC), red cell distribution width 
(RDW). Absolute basophils were not analyzed due to all values equaling zero for both 
groups during pre and post testing. 
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The only marker that exhibited significant change was the platelet count value 
(Model significance p<0.05) and was considered significant at the family-wise level of α 
= 0.05 using a Bonferroni correction at the pretreatment variable level. Despite the 
significant change, the platelet count values remained within the reference ranges (See 
Tables 12 and 13).  This change is not attributed to Mass FX supplementation (Group 
variable p>0.05), but is due to changes from pretreatment values. The remainder of these 
markers did not show any significant change (Model significance p>0.05). 
All markers, except for one subject, MFX2, remained within the reference ranges 
(See Table 18). For this subject, the monocytes and eosinophils were slightly elevated. 
Monocytes were elevated pre- and posttesting; thus, this elevation is independent of 
supplementation. Both changes in monocytes and eosinophils were minor. Possible 
causes for this elevation might be due to infection, stress, and/or inflammation.  
 
 
Table 12 
 Complete Blood Count Results for Mass FX Part 1 a 
Subject     RBC        WBC        Platelets   Hemoglobin  Hematocrit 
    m/mm3   k/mm3    K/mm3              g/dl    % 
Pre     Post  Pre     Post  Pre     Post  Pre     Post  Pre     Post   
   
MFX1    5.29   5.32   4.8      5.6  223     229  15.7    15.8  46.7    47.3 
MFX2    5.28    5.16  5.5      6.9  211     236  16.4    16  47.4    46.6 
MFX3    5.01    5.11  4.5      5.7  211     211  14.7    15.3  43.2    45.5 
MFX4    4.87    4.82  5.3      4.7  266     264  15.1    14.4  43.6    42.3 
Mean    5.11   5.10  5.02   5.72  227.75 235  15.47 15.37  45.22  45.42 
S.D    0.20  0.20  0.45   0.90  26.11   22.01  0.74    0.71  2.13    2.21 
a Notes: Comparison for Mass FX pre/post results on CBC parameter. Reference ranges as provided by 
compunet: WBC 3.8‐10 K/mm3; RBC4.40‐5.8 M/mm3 ; Platelet count 130‐400 K/mm3 ; Hemoglobin: 13.8‐
17.2 g/dl; Hematocrit: 41‐50 %. 
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Table 13 
 Complete Blood Count Results for Placebo Part 1 a 
Subject   RBC    WBC    Platelets  Hemoglobin  Hematocrit 
    Pre     Post  Pre     Post  Pre     Post  Pre     Post  Pre     Post 
PL1    5.17   7.7   7.3      5.16  271     260  15.9    15.8  46.4    46.6 
PL2    5.32   5.38  6.7      5.6  180     188  15.8    16.1  46        47.5 
PL3    4.97   4.65  4.8      5.8  291     261  14.7    13.8  43.3     41.1 
PL4    4.83   4.69  4.4      4.3  246     247  15.2    14.9  43.9     43.2 
Mean    5.07   5.60  5.8      5.2  247     239  15.4    15.15  44.9     44.6 
S.D    0.21   1.43  1.41    0.66  48.31  34.59  0.55    1.03  1.52     2.97 
a Notes: Comparison for placebo pre/post results on CBC parameters. Reference ranges as provided by 
compunet: WBC 3.8‐10 K/mm3; RBC4.40‐5.8 M/mm3; Platelet count 130‐400 K/mm3 ; Hemoglobin: 13.8‐
17.2 g/dl; Hematocrit: 41‐50 %. 
 
Tables 14 and 15 list the values of the changes in the red blood cell indices , 
RDW (Red cell distribution width), MCV (Mean corpuscular volume), MCH (Mean 
corpuscular hemoglobin), and MCHC (Mean corpuscular hemoglobin concentration).  
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Table 14 
 Complete Blood Count Results for Mass FX Part 2 a 
Subject  RDW    MCV    MCH    MCHC 
Pre     Post  Pre     Post  Pre     Post  Pre     Post 
MFX1    12.3    12.4    88.4    88.8  29.7    29.8  33.5   33.5 
MFX2    12.6    12.6  89.7    90.3  31.1    30.9  34.7   34.3 
MFX3    13.5    13.5  86.1    89.1  29.3    29.9  34.1   33.6 
MFX4    11.9    12.1  89.7    87.7  31       29.9  34.1    34.1 
Mean    12.57 12.65  88.47 88.97   30.27 30.12  34.2  33.87 
S.D    0.68   0.60  1.69   1.06  0.91    0.51  0.52  0.386 
a Notes: Comparison for Mass FX™ pre/post results on CBC parameters. Reference ranges as provided by 
compunet:  RDW: 9‐15 %; MCV: 80‐100 fL; MCH: 27‐33 pg; MCHC: 32‐36 g/dl. 
 
 
 
Table 15 
 Complete Blood Count Results for Placebo Part 2 a 
Subject  RDW    MCV    MCH    MCHC 
    Pre     Post  Pre     Post  Pre     Post  Pre     Post 
PL1    13.3    13.1  89.8   90.4  30.8   30.6  34.3    33.9 
PL2    12.6    13.7  86.5   88.3  29.6   29.8  34.3    33.7 
PL3    13.6    12.1  87.1   92.2  29.6   31.8  34       34.4 
PL4    12.2   12.6  91       88.4  31.5   29.9  34.6    33.8 
Mean    12.95 12.87  88.6    89.82     30.37   30.52  34.3     33.95 
S.D    0.63    0.68  2.14     1.85       0.93  0.92  0.24     0.31 
a Notes: Comparison for placebo pre/post results on CBC parameters. Reference ranges as provided by 
compunet:  RDW: 9‐15 %; MCV: 80‐100 fL; MCH: 27‐33 pg/ml; MCHC: 32‐36 g/dl. 
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Table 16 
 Complete Blood Count Results Mass FX Part 3 a 
Subjects  ABS Neut.  ABS Lymph.  ABS Mono.  ABS Eosino.  ABS Baso. 
    Pre     Post  Pre     Post  Pre     Post  Pre     Post  Pre     Post 
MFX1    2.9      3   1.1      1.6  0.5      0.6  0.3       0.4  0  0   
MFX2    2.9     4.2  1.9       1.8  0.5      0.6  0.2       0.2  0  0 
MFX3    2.4      3   1.7      2.1  0.4      0.5   0.1      0.1  0  0 
MFX4    3.2      2.6  1.7      1.7  0.3      0.3  0.1       0.1  0  0 
Mean    2.85  3.2  1.6      1.8  0.42    0.5  0.17     0.2  0  0 
S.D    0.33  0.69  0.34   0.21  0.09    0.14  0.09     0.14  0  0 
a Notes: Comparison for Mass FX™ pre/post results on CBC parameters. Reference ranges as 
provided by compunet: ABS Neut: 1.5‐7.8 K/mm3 ; ABS Lymph  0.9‐4.1 K/mm3;  ABS Mono 0.2‐
1.1 K/mm3 , ABS Eosino 0‐0.6 K/mm3;  ABS Baso. 0‐0.3 K/mm3  
 
 
 
Table 17 
 Complete Blood Count Results for Placebo Part 3 a 
Subjects  ABS Neut.  ABS Lymph.  ABS Mono.  ABS Eosino.  ABS Baso. 
    Pre     Post  Pre     Post  Pre     Post  Pre     Post  Pre     Post 
PL1    4.6      2.6  1.8      2.2  0.9      1   0.1      0.1  0  0   
PL2    4.9      2.7  0.9      2.4  0.8      0.5  0.1      0.3  0  0 
PL3    2.4      2   1.8      1.9  0.3      0.3  0.2      0.1  0  0 
PL4    1.9      3.8  2.1      1.3  0.3      0.4  0.1      0.1  0  0 
Mean    3.45   3.25  1.65  1.95  0.57   0.55  0.12    0.15  0  0 
S.D    1.51   1.11      0.51  0.47  0.32   0.31  0.05    0.1  0  0 
a Notes: Comparison for placebo pre/post results on CBC parameters. Reference ranges as 
provided by compunet: ABS Neut: 1.5‐7.8 K/mm3 ; ABS Lymph  0.9‐4.1 K/mm3;  ABS Mono 0.2‐
1.1 K/mm3 ; ABS Eosino 0‐0.6 K/mm3;  ABS Baso. 0‐0.3 K/mm3   
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Table 18 
 Complete Blood Count Results for Mass FX Part 4 (%)a 
Subject   Neutrophils  Lymphocytes  Monocytes  Eosinophils  Basophils 
    Pre     Post  Pre     Post  Pre     Post   Pre     Post  Pre     Post 
 
MFX1    60.9     53.5   21.9   28   10.1 b  10.5 b   6.5      7.5 b   0.6      0.5 
MFX2    52.4     61.4   35.2   26.5   9.2       8.9   2.8      2.8   0.4      0.4 
MFX3    53.2     52   36.8   37   8.5       8.2   1.3      2.5   0.2      0.3 
MFX4    59.6     54.4   31.9   36.8   6.4       6.6   1.6      1.6   0.5      0.6 
Mean    56.52   55.32  31.45  32.07  8.55     8.55  3.05     3.6  0.42  0.45 
S.D    4.34     4.16  6.68     5.60  1.57  1.61  2.38     2.64  0.17  0.12 
a Note: Comparison for placebo pre/post results on CBC parameters. Reference ranges as 
provided by compunet: Neutrophils : 40‐75 % ; Lymphocytes  17‐47 %;  Monocytes 0‐10 %, 
Eosinophils  0‐7 %;  Basophils 0‐2 %. 
b Minor elevation. 
 
 
Table 19 
 Complete Blood Count Results for Placebo Part 4 (%)a 
Subject   Neutrophils  Lymphocytes  Monocytes  Eosinophils  Basophils 
    Pre     Post  Pre     Post  Pre     Post   Pre     Post  Pre     Post 
PL1    62.7    57.8  24.4    28.1   11.8    13  0.7         0.9   0.4     0.2 
PL2    73.4    46.2   14      40.8   11.4     8.3   0.9        4.4   0.3     0.3 
PL3    50.5     46.5   38.1   44.3   6.5       6.3   4.6        2.3   0.3     0.6 
PL4    43.1      67.5   47       22.7   7.3        8  2.1         1.5          0.5     0.3 
Mean    57.42   54.5  30.87  33.97  9.25  8.9  2.07  2.27  0.37    0.35 
S.D    13.36  10.21  14.59  10.24  2.73  2.87  1.79  1.52  0.09    0.17 
a Note: Comparison for placebo pre/post results on CBC parameters. Reference ranges as 
provided by Compunet: Neutrophils : 40‐75 % ; Lymphocytes:  17‐47 %;  Monocytes: 0‐10 %; 
Eosinophils:  0‐7 %;  Basophils: 0‐2 %. 
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Hypotheses Testing 
In order to ascertain the effects of Mass FXTM on strength, testosterone, clinical 
health markers, and body composition, the following null hypotheses were identified.  
Based upon the results of this study, these hypotheses will now be addressed. 
Ho1: Supplementation with Mass FX™ will not cause an improvement in body 
composition.   This hypothesis was rejected. 
Ho2: Supplementation with Mass FX™ will not cause an increase in total testosterone.  
This hypothesis was not rejected. 
Ho3: Supplementation with Mass FX™ will not cause an increase in free testosterone. 
This hypothesis was rejected. 
Ho4: Supplementation with Mass FX™ will not cause an increase in muscular strength. 
This hypothesis was rejected for the Bench Press only. 
Ho5: Supplementation with Mass FX™ will not cause a change in clinical health markers.  
This hypothesis was not rejected. 
Summary 
 The data analyzed in this section were used to determine if there are any 
significant differences in the results of both groups from pre trial testing. Despite 
apparent improvements in the Mass FX group in the Primary outcomes, only one 
parameter, the bench press was significant (Group variable p<0.05). In all secondary 
outcomes, the results were not significantly affected by the Group variable (all p>0.05). 
Therefore, it is suggested that supplementation with Mass FX does not affect the selected 
clinical health markers.  
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CHAPTER V 
Discussion 
This purpose of this chapter is four fold. First, the chapter will begin with 
discussing the limitations faced in this study followed by a discussion of the major 
findings. Furthermore, this chapter will address the recommendations for future studies. 
Finally, this chapter will end with a conclusion addressing the efficacy of Mass FX. 
Limitations 
Unfortunately, this study had its limitations. A major limitation was the exclusion 
of four subjects, which resulted in a larger variation between groups when comparing 
their respective primary outcome, mean pretrial values. Before exclusion, the means of 
the primary outcomes in between both groups had very little variation compared to after 
exclusion (See Appendix H, Figures 11-17).  
Not only are there group variations, but also there exists inter-subject variation in 
primary outcomes. For example, initial values of testosterone concentrations between 
subjects varied considerably. Some subjects were on the lower end of the reference range 
(especially Mass FX group) whereas others were on the higher end of the reference 
ranges (Placebo). This could be attributed to the different ethnicities represented in this 
study. Various studies have shown apparent differences in androgen levels between 
different racial and ethnic groups (Wu et al., 1995; Ellis et al., 1992; Ross et al., 1986; 
Winters et al., 2001). Hence, this should be considered when analyzing the data. Not only 
that, but there are other factors that might influence baseline testosterone concentrations. 
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These factors include genetics, hormonal regulation, health status, activity levels, diet, 
external factors, and emotions (Warren & Constantini, 2000, p.3).  
Another inter-subject variation was the initial strength values. These variations 
could be attributed to previous weight training experience mode, bodyweight, aggression, 
and motivation of the subjects. Therefore, keeping all of these aforementioned factors in 
mind, this study should strictly be considered a pilot study until future studies are 
performed with better recruiting strategies and larger samples sizes.  
There were various reasons that led to the exclusion of the subjects. In detail, two 
subjects from each group were excluded from the trial. The first subject in the Placebo 
group abruptly stopped working out and taking the supplementation and decided not to 
continue the trial. While, the second subject in the same group suffered from 
streptococcal pharyngitis and was taking medications including Ambien ™, amoxcillian, 
and a dietary supplement, ZMA®. 
In the Mass FX group, one subject was excluded due to diagnosis of a 
hematological anomaly. Initial blood testing showed signs of microcyctic anemia. 
Analysis revealed moderate levels of unequal red blood cell size (anisocytosis). In 
addition, a marked presence of very small red blood cells (microcytosis) was observed 
and giant platelets were noted. There was also a slight variation in the hemoglobin 
content in his red blood cells (polychromasia). There was a presence of moderate 
amounts of elliptocytes (ovalocytes), oval shaped red blood cells, in his blood samples. 
Furthermore, the blood analysis revealed low hemoglobin (10.6 g/dl), hematocrit (34.3 
%), MCV (58.3 fL), MCH (18 pg), and MCHC (30.8 g/dl).  Finally, high values for both 
RDW (19.6 %) and RBC count (5.87 m/mm3) were noted.  
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The second Mass FX subject was excluded for not following recommended 
dietary guidelines, especially fat intake. His fat calories were around 5-10 % of total 
calories. This was about 15-20 % difference between the recommended guidelines (25 % 
fat calories from total calories). For the sake of the study, it was necessary to have a 
higher fat intake as it is crucial for testosterone production. Dorgan et al. (2000) have 
shown that diets with low fat intakes are associated with lower androgen production in 
comparison to higher fat diets. Also, Hamalainen et al. (1983) have shown that dietary fat 
intake less than 25% of total calories reduces androgen concentrations in healthy men. 
Therefore, the 25% fat calories utilization in this study was based on Hamalainen et al.’s 
findings. Thus, any subject whose fat intake was lower than recommended was excluded 
from this study. Not only that, but fat may play a role in exercise induced testosterone 
increases that may contribute to better hypertrophy adaptations (Sallinen, 2007). Hence, 
low fat intakes may negate this benefit.  
Discussion 
Surprisingly, the Placebo group had major reductions in both total and free 
testosterone. This observation could be explained by the intensive training program that 
the subjects underwent. Studies involving intensive training have shown significant 
reductions in testosterone concentrations (Flynn et al., 1994). In addition, these decreases 
may suggest an incomplete recovery from intense training (Vervoorn et al., 1991). 
Interestingly enough, the lower testosterone concentration didn’t reduce the muscular 
strength of the subjects in comparison to pretrial strength measurements. These findings 
were similar to the study by Vervoorn et al. (1991) which showed that a lower 
testosterone/cortisol ratio did not negatively affect exercise performance.  
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Despite compliance to diet and training, the Placebo group showed minor to no 
improvements in the 1 repetition max strength tests. Various factors affect muscle 
strength. One such factor to consider is limb length because individuals with longer limbs 
are at a biomechanical disadvantage. Another factor to keep in mind is possible 
overtraining/overreaching due to the intensive training program, which may result in 
muscle and central nervous system fatigue. The training protocol in this trial was 
considered high volume in nature. Interestingly, Moore & Fry (2007) have shown that 
high volume training can result in poor performance with significant decreases in 
testosterone concentrations. These results closely resemble the findings in this trial. 
Therefore, it is suggested that Mass FX might help in offsetting some overreaching 
symptoms since the Mass FX group was void of any overreaching/overtraining 
symptoms. 
Only one subject in the Placebo (PL2) had his total testosterone increase from 
pretesting. The increase was not significant, but a change of 1.2 % was noted (See Table 
7). This could be a result of the body trying to compensate for the decrease in free 
testosterone via feedback mechanisms (See Figure 8).  
As for testosterone observations for the Mass FX group, all subjects reported 
impressive improvements in free testosterone. A study conducted by Ahtiainen et al. 
(2003) suggested that increases in basal testosterone levels might be a significant factor 
in considering strength improvements. Interestingly enough, the Mass FX group had 
obvious increases in basal free testosterone levels in comparison to pretrial basal values 
and greater improvements in strength compared to Placebo. Thus, it is suggested that 
there might be a correlation between muscular strength and free testosterone levels in the 
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Mass FX group.  Therefore, it may be valid to assume that the increases in strength in the 
Mass FX group might be attributed in part to the increases in free testosterone.  
 The mean percent difference increase in free testosterone from pretesting was 
75.84 %. In addition, excluding the two subjects (MFX2 and MFX4), all exhibited 
increases in total testosterone concentrations – the subjects had minor drops (2.9 and 7.07 
%, respectively). Generally, total testosterone concentrations change in relation to 
changes in free testosterone concentrations via SHBG concentrations (Kelly & 
Vankrieken, 1997; Nieschlang et al., 2004, p.643). This is due to the fact that free and 
protein bound testosterone in blood are in state of equilibrium (Nieschlang et al., 2004, 
p.643). Therefore, any changes in the concentration of free testosterone levels would 
result in changes in total testosterone levels. For example, increased SHBG 
concentrations reduce free testosterone and increases total testosterone (Anderson, 1974); 
therefore, it is suggested that an inverse relationship might exit between these three 
clinical markers. Thus, a rise in free testosterone via SHBG might result in a decrease in 
total testosterone and vice versa. It would have been interesting to determine whether the 
changes in total and free testosterone were a result of SHBG concentration differences. 
This could have been achieved by analyzing SHBG concentrations via a blood analysis. It 
is suggested that the apparent increases in free testosterone due to Mass FX (probably via 
SHBG inhibition) caused this decrease in total testosterone concentrations of subjects 
MFX2 and MFX4. These minor reductions could be attributed to a homeostatic 
mechanism in which the body is trying to regulate the balance of bioavailable and bound 
testosterone. Due to these possible changes, it would be recommended to use Mass FX in 
microcycles of six weeks as exemplified in this study. This is recommended to prevent 
any possible reductions in total testosterone via feedback inhibitions in response to 
elevated serum free testosterone levels.  
In addition to SHBG regulation, testosterone concentrations are regulated by 
negative feedback loops to the hypothalamus and anterior pituitary (See Figure 8). An 
increase in testosterone concentrations signals the hypothalamus to decrease secretion of 
GnRH, which in turn decreases gonadtropin production. Not only that, but increased 
testosterone levels also contributes to less LH secretion in response to GnRH from the 
anterior pituitary (Widmaier et al., 2004, p.654-655). This might explain the total 
testosterone increase in the placebo subject (PL2). 
 
Figure 10: Regulation of testosterone via feedback mechanisms (Widmaier et al., 2004, p.654)
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As for side effects,  no adverse events were reported by any of the subjects for 
both groups.  However, the Mass FX group reported increases in libido. This effect was 
reported during the 2nd and 3rd week of the trial. 
To determine the power of the samples used in this study, a posthoc Power 
Analysis (See Table 22) was performed to test an effect for Mass FX (if it existed). It was 
determined that the data required an 88.6% power level to detect the effect of Mass FX 
for the bench press outcome which was achieved.  This indicates that the bench press 
significance was valid.  There was nearly 80% power for the Free Testosterone outcome, 
indicating that Mass FX might have had a significant effect if the sample size was larger.  
The other tests had very low power to detect the effect of Mass FX, if it exists. For those 
variable, it is not certain if the lack of significant change was due to the small sample size 
or the lack of a real effect.   
As for the secondary outcomes, the clinical health marker variables, the power 
was very low for all. The conclusion that Mass FX did not appear to have an effect on 
these markers (It was not possible to reject the null hypothesis that it had no effect), is 
more likely due to the fact that there was insufficient power (small sample size) to see 
that effect, if it existed.  
Recommendations 
 A suggestion that would have made this study better, would have been to use 
larger sample sizes in both groups. However, due to limitations during recruiting and 
exclusion of four subjects, the resulting sample size was eight subjects total with four 
subjects in each group. In turn, this trial may be considered a pilot study.  
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In addition, future studies should measure muscle circumferences from various 
parts of the body such as arm, calves, thighs, and chest/back to determine whether Mass 
FX supplementation induces larger circumference changes than Placebo. Not only that, 
but measuring muscle cross sectional areas of specific muscle groups such as thighs is 
another  parameter to address in future studies. This could illustrate whether Mass FX 
supplementation induces larger muscle hypertrophy responses than Placebo. These 
measures can be obtained by using computed tomography (CT), magnetic resonance 
imaging (MRI), and/or dual-energy X-ray absorptiometry (DEXA). 
Another recommendation for future studies would be measuring other clinical 
parameters such as SHBG. This would help in drawing conclusions as to whether the 
increases in free testosterone were a result of a decrease in SHBG production (as 
mentioned earlier). Measurement of other clinical markers such as testosterone 
metabolites, namely dihydrotestosterone (DHT) and estrogen (E), would be considered 
valuable. Quantifying E would help in investigating whether Mass FX modulates 
aromatase, an enzyme involved in the metabolism of testosterone into estrogen. In turn, 
this would explain if the total testosterone increases in the Mass FX group were due to 
feedback mechanisms via aromatase/estrogen inhibition as observed with other studies 
involving aromatase inhibition (Willoughby et al., 2007; Rohle et al., 2007). 
Analyzing muscle samples for myogenic regulatory factors (MRFs) would have 
been an interesting addition to the set of data compiled in this study. MRFs such as 
MRF4, MyoD and Myf5, have been shown to be involved in muscle fiber adaptations 
during hypertrophy (Hespel et al., 2001). Thus, by analyzing the expression of these 
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regulatory factors, conclusions can be made to see if Mass FX has an effect on MRFs and 
correlate the findings to hypertrophy measures such as lean mass gain. 
 
Conclusion 
In conclusion, this study suggests that Mass FXTM has ergogenic benefits when 
taken during a controlled diet and exercise program. The data also suggest that Mass 
FXTM does not affect selected clinical health markers such as CBC with differentials, 
hepatic, renal, and lipid profiles and thus, appears safe when taken within recommended 
doses. It is recommended that future studies should utilize larger sample size to obtain 
statistical significance of findings.  
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APPENDIX A 
AHA/ACSM HEALTH/FITNESS FACILITY PREPARTICIPATION SCREENING 
QUESTIONNAIRE. 
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APPENDIX B 
INFORMED CONSENT 
 
 
                                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Department of Biological  Sciences 
Exercise Biology Program 
3640 Colonel Glenn Hwy 
Dayton, OH 45435-0001 
(937) 775-2655 
FAX (937) 775-3320  
 
 
INFORMED CONSENT 
 
TITLE: Effects of a combination of plant extracts, chlorogenin and (-)-3,4 
divanillyltetrahydrofuran, on exercise performance, body composition, and blood 
chemistries in adult males. 
 
Please read this entire informed consent.  It will explain procedures for which your 
consent and participation are requested. 
 
AGREEMENT TO PARTICIPATE:  I have been asked to participate in this 
research study because I am between 21-30 years of age, have had at least six months of 
weight lifting experience, and am healthy.  This signed consent is to certify my 
willingness to participate in this research study. 
 
PURPOSE OF STUDY: This study is designed to determine the effects of the 
dietary supplement, Mass FX™, on exercise performance, body composition, and blood 
chemistries in experienced resistance-trained (weight trained) males.. It is also expected 
that testosterone (free testosterone) levels will be significantly elevated, while health 
markers (liver enzymes (alanine transaminase, aspartate transaminase), RBC and WBC 
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counts, lipid profiles (total cholesterol/ LDL/HDL), and kidney function (creatinine/blood 
urea nitrogen) remain significantly unchanged. 
 
PROCEDURES:    All testing procedures will be performed in the Exercise Biology 
Laboratory at Wright State University according to the following schedule. All training 
will take place at the WSU Fitness Center. 
 Week 0: 
• Visit 1: Complete a Health history and demographic questionnaire, as well as 
answer questions about my health and exercise history.  Read and sign a consent 
form, have my resting blood pressure,  resting heart rate, height, and weight 
measured, complete a Pre-trial body composition analysis, and have a teaspoon 
of blood drawn from my forearm. This visit will last about 1 hour. 
Eligibility determination 
To insure that I am “apparently healthy” as recommended by the American College 
of Sports Medicine Guidelines (ACSM, 2006) for participating in sports and physical 
activity, I will fill in an AHA/ACSM Health/Fitness Facility Preparticipation Screening 
Questionnaire  prior to engaging in this study.  
To be eligible for this study, I can have no more than one coronary artery disease risk 
factor and no signs/symptoms of metabolic, endocrine, or cardiopulmonary disease. In 
addition, I cannot be taking any taking any medication [prescription or over-the-counter] 
or other nutritional supplements before and during the study period.  
 
Informed consent 
After determining eligibility status, the primary investigator (Mr. Patrick Dib) will 
fully explain the procedures and methodology involved in the study to me. Mr. Dib will 
also answer all questions that I may have. I am aware that my participation is voluntary 
and that I reserve the right to withdraw at any time without penalty.  
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Demographics 
After signing the informed consent, the primary investigator will begin to obtain 
measurements for the pre-study parameters from me. First, the primary investigator will 
gather my demographic information, which includes my initials, date of birth, height, 
blood pressure, heart rate, body weight, and body fat. 
 
Other Measurements  [These measurements will take approximately 1 hour] 
Resting blood pressure will be measured by using a Marshall medical measuring kit. 
The systolic and diastolic portions of the blood pressure will be taken. In a seated 
position (legs uncrossed), measurements will be taken with my left forearm positioned on 
a cushion on a table at heart level. Blood pressure measurements will be recorded twice  
with 5 minutes rest in between each reading. The average of both readings will be 
recorded. However, if there is more than a five mmHg difference between the 2 readings, 
a third reading will be performed after a 5 minute rest. The average of all 3 readings 
would be recorded in this case. 
Resting heart rate will be measured using a polar heart rate monitor while I am 
sitting in a chair (legs uncrossed). The investigator will attach the transmitter to the 
elastic strap, adjust and secure the strap to my chest just below the chest muscles. Finally, 
the investigator will lift the transmitter up and moisten the grooved electrode areas with 
water on the back and make sure that the electrode is firmly against my skin and that the 
Polar logo is in a central, upright position (Polar, 2002). 
Height will be measured without shoes and socks to the nearest 0.1 inch using a 
stadiometer [an instrument for measuring height] (SECA, 2006, Germany). Prior to 
taking the measurement, I will be asked to stand with both feet and heels together and 
arms at my side. I will be directed to keep my head level with my eyes fixed straight 
ahead. 
Body fat and weight will be measured via a recently calibrated BOD/POD 
(1997,Concord, CA). I will wear spandex or compression shorts and remove all jewelry 
and accessories. I will be given a Speedo© head cap to cover my hair.   
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I will step into the Bod Pod device and sit down with my hands folded in my lap.  I 
will breathe normally and sit quietly until the assessment is complete.  The entire test will 
take approximately five minutes. 
• Visit 2:  Muscle strength testing  This visit will last about 1 hour. 
 I will be asked to perform a  three muscular strength tests. These tests will be 
done in a 1 Repetition Maximum (1-RM) manner. 1-RM tests are performed in a gradual 
fashion with added weight on each trial until I cannot perform a complete lift in good 
form. I will start my lifts with a low weight. If I perform the lift properly, five pounds 
will be added to the next attempted lift. This will continue until I can no longer lift the 
specified amount of weight. The last amount of weight lift complete and in good form 
will be recorded as my 1 RM. During these tests, a spotter will be available to minimize 
the risk of injury and to ensure the proper execution of the exercises.  The three tests I 
will perform are the bench press, leg press, and deadlift.  
Bench Press 
The procedures for the bench press are as follows: 
1. With the barbell on the rack, I will lie on the bench so that the bar is above my 
head. 
2. I will bring my hands up and hold the bar just wider than shoulder width apart.  
3. I will lift the barbell off the rack and extend my arms until they're straight. 
4. Then I will slowly lower the weight until the bar almost touches my chest. 
5. I will slowly lift the weight back up. 
6. Spotters will be on either side of the bar to assist the lift. 
Leg Press    
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The procedures for the leg lift are as follows:  
1. I will sit in the leg press machine with my body at a 45o angle and my feet about 
shoulder width apart  
2. The bars will be released. 
3. I will push the plate away until my legs are straight. 
4. I will slowly return to starting position. 
5. Spotters will be at my side to assist the lift. 
Deadlift 
The procedures for the deadlift are as follows: 
1. With the barbell on the floor, I will squat down and hold the bar at about shoulder 
width. My back will be straight. 
2. With my back straight, I will slowly lift the weight until I am standing straight.  
3. This position will be held for a second. 
4. The weight will be slowly lowered back to the floor. 
• Visit 3: This visit will last about 30 minutes. 
o Review resistance training protocol  
o Review supplementation protocol  
o Review of dietary recommendations  
Training Protocol 
         I will be asked to perform a specific exercise program 3 times a week with 
recommendations on what I should eat while training (see attached). I will not perform 
76 
 
any additional exercise outside the study. I will be monitored on every workout session 
by Mr. Dib or a trained senior Exercise Biology major to ensure all safety precautions are 
in followed and observed for any health changes.  Mr. Dib will call me by phone, daily,  
to ensure that I am not having any health problems.  
Supplementation Protocol and Dietary Recommendations  
 I will be asked to take 1 supplement capsule 4x/day. One capsule will be taken 
with breakfast, another capsule with lunch, another capsule with a midday snack, and the 
final capsule will be taken with dinner. Each capsule will be taken with a full glass of 
water. 
 I will be asked to record the times in which I take the supplement on a 
supplementation log (attached).  
 During the six weeks of training, I will be asked to try and eat a healthy and 
balanced diet.  I will be given a recommended diet. (attached). 
 I will be asked to record my diet for the duration of the study on a diet log. 
Weeks 1-6: Training at the WSU Fitness Center 
Week 7: 
• Visit 1: Post trial body composition testing; post trial blood draw  
• Visit 2: Post trial muscle strength testing\ 
These tests are identical to the tests performed on visits 1 and 2 in week 0.  
BENEFITS AND RISKS: I understand that there is risk of muscle soreness as a result of 
exercise testing and the workout program. In addition, there is risk of injury when 
performing exercise; however, I will be supervised by the primary investigator and his 
assistants to minimize this risk. I also understand that supplementing my diet with Mass 
FX® may cause some acne, oily skin, increased body hair, and/or minor hair shedding 
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because of elevated testosterone levels. In addition, as with any nutritional supplement, 
Mass FX™ may carry rare incidences of unknown risks. Also, at the site where a small 
sample of blood will be taken (venipuncture), a small bruise and soreness may develop.  
The benefits to my participation in this study include the knowledge gained from data 
collected from my exercise performance, body composition, and blood chemistries. I may 
also benefit from an organized and supervised workout program. Finally, I will be given 
all my individual results of the testing performed in this study.  
ADDITIONAL COSTS: There is no cost to me to participate in the study.  
 
ALTERNATIVES: There are no alternatives to this procedure 
 
REMUNERATION: There is no compensation for this study. 
 
CONFIDENTIALITY:   . Participation in research may involve a loss of privacy, but 
information about me will be handled as confidentially as possible.  All personal 
information will be kept in a file cabinet in the exercise biology office. Finally, I am 
aware that only the primary investigator and the thesis chair will have access to my 
information. The access to my information is strictly for academic purposes.  My name 
will not be included if these data are presented in written or oral form.  Only group and 
nonidentifiable individual results [e.g., Subject 1, Subject 2, etc.]  will be reported. 
Because of the nature of the pre-and posttests, you will know your scores on the body 
composition, resting blood pressure, resting heart rate, and body composition.   
 
Keeping Study Records: Mr. Dib will retain my research records, including information 
from my medical history form, indefinitely for research purposes. However, my personal 
health information cannot be used for additional research without additional approval 
from me. 
 
COMPENSATION/LIABILITY STATEMENT:  You will receive medical help if 
injured in this research study.  You and/or your health plan will be charged for this 
treatment.  The study will not pay for medical treatment.   
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EXPLANATION RECEIVED: I hereby acknowledge that this study has been 
explained to me and that the principal investigator (Mr. Patrick Dib) has discussed the 
possible risks and side effects associated with this study. I also certify that I was given 
the opportunity to have all my questions answered by the primary investigator regarding 
this study. 
 
QUESTIONS / CONTACT PERSONS:  For more information about this study, or in 
the unlikely event of injury, I may contact Mr. Patrick Dib, primary investigator at 310-
570-6359 (cell) or Roberta Pohlman, Ph.D., Director, Exercise Biology Program at 937-
775-2858 [Department of Biological Sciences, 265 Biology Hall, 775-2655] .  I may also 
contact the WSU Institutional Review Board at 201J University Hall, Wright State 
University, Dayton, Ohio 45435,  (937) 775-4462. 
 
 Obtaining Results:  If you would like to receive the values for your blood 
chemistry and the study results when evaluated we will provide you with a self-addressed 
postcard requesting this information at the end of the study 
 
VOLUNTARY CONSENT:  PARTICIPATION IN RESEARCH IS VOLUNTARY.  I 
hereby reserve the right to refuse to participate in this study or to withdraw at any given 
time. My decision to participate or not to participate will not negatively affect my care at 
this institution or cause a loss of benefits to which I might otherwise be entitled.  I may 
also withdraw my conset for this study to use my personal health information by contacting 
Patrick Dib to inform him of my decision. If I withdraw my consent, the information 
already collected may continue to be used, to maintain the integrity of the study 
 
My signature below means that I have freely and willingly and without any external 
influence, agreed to participate in this aforementioned research study. 
 
Signature/Date Lines:  
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______________________________________________________________________ 
Printed Name of Participant 
 
______________________________________________________________________ 
Signature of Participant      Date 
 
 
Signature of Witness      Date 
 
________________________________________________________________________ 
Signature of Primary Investigator     Date 
 
Mr. Patrick Dib 
235 Biological Sciences 
College of Science and Math 
775-2858 
dib.2@wright.edu 
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APPENDIX C 
DIETARY RECOMMENDATIONS 
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Dietary intake is customized to each subject as follows: 
• Total calories: 
 
Total caloric intake: (Bodyweight * 14) + 500 
 
• Protein: 
 
1.2g/lb of bodyweight = Protein intake in g/day 
 
1.2g/lb of bodyweight * 4 = Total calories from protein/day 
 
 
• Fats:  
 
Total caloric intake * 0.2 = Total fat calories/day 
 
Total fat calories/9 = amount of fat in g/day 
 
 
• Carbohydrates: 
 
Total calories from carbs:  Total caloric intake- (Total protein calories/day + Total 
fat calories/day). 
 
Total calories from carbs / 4 = Total grams of carbs/day 
 
After determining the amount of each macronutrient subjects were recommended to use 
the following food choices to reach their recommended caloric intake. 
  
Protein: Lean red meats, poultry, pure whey protein powder, egg whites, fish 
Carbohydrates: whole wheat bread and pasta, brown rice, oats, yams, sweet  
potatoes, veggies 
Fats: olive oil, nuts, egg yolk, natural peanut butter, fish fats,  
 
Supplements:  4 caps/day split as follows: 
 
1 capsule 15-20 minutes before breakfast, lunch and dinner 
1 capsule 30-45 minutes pre-workout. 
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APPENDIX D 
WORKOUT PROGRAM 
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Upper: Monday/Thursday 
 
Flat Bench: 3 sets 8-10 reps 
Incline Bench: 3 sets 8-10 reps 
Military Press: 3 sets 8-10 reps 
Upright rows: 2 sets 8-10 reps 
DB rows: 2 sets 8-10 reps 
Barbell Rows: 3 sets 8-10 reps  
pulldowns: 3 sets 8-10 reps 
Cleans: 1 set 15-20 (Light Weight, feel the burn) 
Barbell Curls: 2 sets 8-10 reps 
French Curls: 2 sets 8-10 reps 
 
 
Lower: Tuesday/Friday 
 
Deadlift: 3 sets 8-10 reps 
Leg Press: 3 sets 8-10 reps 
 
Superset*: 3 sets 8-10 reps  
-Leg Extension 
-Leg curls 
 
Back squats: 1 sets 15-20 (light weight, slow tempo) 
Leg Press: 2 sets 15-20 (light weight, slow tempo) 
 
 
Seated Calf raises: 3 sets 8-10 (Slow rep tempo) 
Standing or donkey Calf raises: 3 sets 8-10 (Slow rep tempo) 
*: superset denotes that the 2 exercises should be done back to back . Subject should 
rest after both exercises are done. Then repeat for given amount of sets. 
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APPENDIX E 
DEMOGRAPHICS 
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Subject Name:         ID# 
 
 
Date of Birth: 
 
 
Height (inches): 
 
 
Weight (pounds): 
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APPENDIX F 
SELECTED CLINICAL HEALTH MARKERS 
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Complete blood count: White blood cell count (WBC),  White blood cell differential: 
(neutrophils lymphocytes, monocytes, eosinophils, basophils,), Absolute neutrophils, 
Absolute lymphocytes, Absolute monocytes, Absolute eosinophils, Absolute basophils. 
Red blood cell count (RBC), Hemoglobin, Hematocrit, platelet count, Mean corpuscular 
volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin 
concentration (MCHC), Red cell distribution width (RDW). Lipid Profile: Low Density 
Lipoprotein (LDL), High Density Lipoprotein (HDL) , Very Low Density Lipoprotein 
(VLDL), Triglycerides (TG), Total cholesterol (TC). Hepatic: Alkaline phosphatase 
(ALP),  Aspartate aminotransferase (AST), Alanine aminotransferase (ALT). Renal: 
Creatinine, Blood Urea nitrogen (BUN).  
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APPENDIX G  
STATISTICAL ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 20 
 Primary Outcomes statistical analysis 
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Table 21* 
Secondary Outcomes statistical analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Notes: ALT,AST,LDL,HDL,Total Cholesterol, and creatinine were not                        
considered significant models after applying the Bonferroni correction. 
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Table 22: Posthoc Power analysis 
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APPENDIX H 
VARIATION FIGURES 
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Figure 11:Comparison of pretrial free testosterone variation before and after exclusion of subjects. 
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Figure 12: Comparison of pretrial total testosterone variation before and after exclusion of subjects. 
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Figure 13:Comparison of pretrial fat free mass variation before and after exclusion of subjects. 
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Figure 14:Comparison of pretrial fat mass variation before and after exclusion of subjects. 
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Figure 15: Comparison of pretrial bench press variation before and after exclusion of subjects. 
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Leg Press
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Figure 16: Comparison of pretrial leg press variation before and after exclusion of subjects 
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Figure 17: Comparison of pretrial deadlift variation before and after exclusion of subjects 
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